[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 666
1. Singer M, Mutch MG: Anal melanoma. Clin Colon Rectal Surg; 2006 May;19(2):78-87
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal melanoma.
  • Anal melanoma is rare and aggressive malignancy.
  • Unlike cutaneous melanoma, anal melanoma has no known risk factors.
  • There are no long-term survivors of stage II or III disease; therefore, early diagnosis and treatment remain crucial.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1341-8 [10219070.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5 [10522715.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] Oncology (Williston Park). 1999 Nov;13(11):1561-74; discussion 1574 passim [10581603.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):863-7 [10741708.001]
  • [Cites] Recent Results Cancer Res. 2000;157:178-89 [10857171.001]
  • [Cites] Curr Oncol Rep. 2000 Jul;2(4):292-9 [11122856.001]
  • [Cites] Chir Ital. 2000 Jul-Aug;52(4):329-34 [11190522.001]
  • [Cites] South Med J. 2001 Sep;94(9):880-5 [11592745.001]
  • [Cites] Tech Coloproctol. 2001 Apr;5(1):51-4 [11793262.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1818-25 [11919239.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72 [11958890.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9 [12368672.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):395-8 [12170190.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1545-8 [12397731.001]
  • [Cites] Histopathology. 2002 Dec;41(6):519-25 [12460204.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(1):53-6 [12630771.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]
  • [Cites] Radiology. 2004 Jul;232(1):181-6 [15220501.001]
  • [Cites] Anticancer Drugs. 2005 Mar;16(3):345-8 [15711188.001]
  • [Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]
  • [Cites] Int Surg. 1980 Sep-Oct;65(5):423-6 [7451062.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3 [7473820.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):118-20 [7844981.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:167-77 [8368735.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):81-6 [8409692.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Histopathology. 1993 Mar;22(3):261-4 [8495957.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):88-94 [10618610.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):87-97 [10761786.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):680-4 [11034246.001]
  • [Cites] Surg Today. 2001;31(6):527-9 [11428607.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):53-9 [11719029.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]
  • [Cites] Can J Surg. 2003 Oct;46(5):345-9 [14577706.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Arch Surg. 1990 Mar;125(3):313-6 [2306178.001]
  • [Cites] Radiother Oncol. 1989 Nov;16(3):169-82 [2587808.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1364-70 [3345491.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]
  • [Cites] Acta Chir Scand. 1974;140(1):68-72 [4819025.001]
  • [Cites] CA Cancer J Clin. 1966 May-Jun;16(3):111-4 [4957071.001]
  • [Cites] Dis Colon Rectum. 1967 May-Jun;10(3):161-76 [6026797.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1299-305 [6362841.001]
  • [Cites] Am J Surg. 1983 Sep;146(3):336-8 [6614323.001]
  • [Cites] N Engl J Med. 1982 Oct 7;307(15):913-6 [7050717.001]
  • [Cites] Surg Gynecol Obstet. 1982 Mar;154(3):337-41 [7064068.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):772-7 [7172945.001]
  • [Cites] Br J Surg. 1981 Sep;68(9):667-8 [7272698.001]
  • [Cites] Dis Colon Rectum. 1980 Mar;23(2):122-4 [7379659.001]
  • [Cites] Arch Surg. 1996 Sep;131(9):975-9; 979-80 [8790168.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):827-35 [8922197.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Surg Oncol. 1996 Aug;5(4):165-8 [9067564.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Mar;16(1):81-5 [9148866.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Surg Today. 1997;27(8):753-6 [9306593.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9 [9660028.001]
  • [Cites] Eur J Surg Oncol. 1998 Aug;24(4):303-7 [9724998.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2921-9 [9738559.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]
  • [Cites] Acta Oncol. 1998;37(5):497-9 [9831382.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S22-6 [9849405.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 [9862627.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):476-80 [9887254.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]
  • (PMID = 20011314.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780102
  • [Keywords] NOTNLM ; Melanoma / abdominoperineal resection / anal / malignancy / wide local excision
  •  go-up   go-down


2. Mistrangelo M, Bellò M, Mobiglia A, Beltramo G, Cassoni P, Milanesi E, Cornaglia S, Pelosi E, Giunta F, Sandrucci S, Mussa A: Feasibility of the sentinel node biopsy in anal cancer. Q J Nucl Med Mol Imaging; 2009 Feb;53(1):3-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of the sentinel node biopsy in anal cancer.
  • AIM: Anal cancer is a rare neoplasm.
  • According to a European Organization for Research and Treatment of Cancer multivariate analysis, synchronous inguinal lymph node metastasis occurs in 10-25% of patients and constitutes an independent prognostic factor for local failure and overall mortality.
  • METHODS: Inguinal lymph node status was assessed using the sentinel node technique in 35 patients with anal cancer.
  • RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular epithelioma associated with areas of Bowen's disease.
  • Disease stage was T1 in 5 patients, T2 in 18, T3 in 11 and T4 in 1 patient.
  • CONCLUSIONS: Given the correlation between prognosis and node involvement, sentinel node biopsy can be considered a simple method for adequate pretreatment staging of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / diagnosis. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Recurrence

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337684.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


Advertisement
4. Wargovich MJ, Morris J, Brown V, Ellis J, Logothetis B, Weber R: Nutraceutical use in late-stage cancer. Cancer Metastasis Rev; 2010 Sep;29(3):503-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutraceutical use in late-stage cancer.
  • Access to a wealth of information on the internet has led many cancer patients to use complementary methods as an adjunct to traditional therapy for cancer, with, and more often, without informing their primary caregiver.
  • Of the common complementary modalities, the use of dietary supplements appears to be highly prevalent in patients in active treatment for cancer, and later in cancer survivors.
  • Emerging research suggests that some plant-based agents may, indeed, impact late-stage cancer, influencing molecular processes corrupted by tumor cells to evade detection, expand clonally, and invade surrounding tissues.
  • The intent of this article is to review some of the current science underpinning the use of nutraceuticals in the latter stages of cancer.

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Nutr Food Res. 2010 Jul;54 Suppl 2:S196-204 [20461740.001]
  • [Cites] Life Sci. 2010 Jun 19;86(25-26):936-41 [20434464.001]
  • [Cites] Arch Biochem Biophys. 2010 Sep 1;501(1):52-7 [20361925.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2505-14 [10893280.001]
  • [Cites] J Agric Food Chem. 2000 Nov;48(11):5206-10 [11087460.001]
  • [Cites] Ann Pharmacother. 2000 Dec;34(12):1478-82 [11144706.001]
  • [Cites] CA Cancer J Clin. 2001 Jul-Aug;51(4):232-48; quiz 249-52 [11577489.001]
  • [Cites] Semin Oncol Nurs. 2001 Nov;17(4):236-40 [11764706.001]
  • [Cites] Clin Exp Metastasis. 2002;19(8):703-8 [12553376.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):248-66 [12903014.001]
  • [Cites] Integr Cancer Ther. 2003 Sep;2(3):247-67 [15035888.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):155-60 [8049637.001]
  • [Cites] J Pain Symptom Manage. 1995 Apr;10(3):243-8 [7629418.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):777-82 [9708945.001]
  • [Cites] Mayo Clin Proc. 2005 Jan;80(1):55-60 [15667030.001]
  • [Cites] J Cell Biochem. 2010 Oct 15;111(3):742-54 [20626034.001]
  • [Cites] Biofactors. 2010 Sep-Oct;36(5):360-9 [20623546.001]
  • [Cites] Invest New Drugs. 2011 Feb;29(1):110-7 [19851710.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3396-403 [15833874.001]
  • [Cites] Drugs. 2005;65(9):1239-82 [15916450.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1851-8 [16452247.001]
  • [Cites] Integr Cancer Ther. 2006 Mar;5(1):9-29 [16484711.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1463-73 [16331273.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):885-91 [16969510.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):223S-228S [17182830.001]
  • [Cites] Cancer Lett. 2007 Oct 8;255(2):194-204 [17555873.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1978-84 [17638923.001]
  • [Cites] Front Biosci. 2008;13:440-52 [17981559.001]
  • [Cites] Crit Rev Food Sci Nutr. 2007;47(8):735-48 [17987447.001]
  • [Cites] Hawaii Med J. 2007 Dec;66(12):326-7 [18269091.001]
  • [Cites] BMC Complement Altern Med. 2007;7:44 [18096028.001]
  • [Cites] J Appl Toxicol. 2008 Mar;28(2):156-63 [17541943.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2024-32 [18339885.001]
  • [Cites] J Nutr Biochem. 2008 May;19(5):313-9 [17683926.001]
  • [Cites] Respir Res. 2008;9:33 [18426555.001]
  • [Cites] Cancer Lett. 2008 Aug 18;267(1):133-64 [18462866.001]
  • [Cites] Br J Cancer. 2008 Aug 19;99(4):647-54 [18665171.001]
  • [Cites] Mol Nutr Food Res. 2008 Sep;52(9):1010-30 [18384098.001]
  • [Cites] Planta Med. 2008 Oct;74(13):1560-9 [18612945.001]
  • [Cites] Apoptosis. 2008 Dec;13(12):1465-78 [19002586.001]
  • [Cites] Mol Nutr Food Res. 2008 Dec;52(12):1381-98 [19065593.001]
  • [Cites] Inflammopharmacology. 2008 Oct;16(5):219-26 [18815740.001]
  • [Cites] Nutr Cancer. 2009;61(1):27-35 [19116873.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):583-92 [19147572.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Mar;328(3):829-38 [19066340.001]
  • [Cites] Support Care Cancer. 2009 May;17(5):563-72 [19005687.001]
  • [Cites] Forum Nutr. 2009;61:182-92 [19367122.001]
  • [Cites] Crit Rev Food Sci Nutr. 2009 May;49(5):463-73 [19399671.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):961-7 [19384950.001]
  • [Cites] Cell Mol Biol Lett. 2009;14(3):497-510 [19381455.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(3):CD005004 [19588362.001]
  • [Cites] Mutat Res. 2009 Jun-Jul;677(1-2):46-52 [19501671.001]
  • [Cites] Chem Biol Interact. 2009 Sep 14;181(1):77-84 [19481070.001]
  • [Cites] Breast J. 2009 May-Jun;15(3):223-9 [19645775.001]
  • [Cites] Phytother Res. 2009 Sep;23(9):1197-204 [19140172.001]
  • [Cites] Ann N Y Acad Sci. 2009 Aug;1171:538-44 [19723101.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2187-97 [19623659.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):534-42 [19735878.001]
  • [Cites] Mol Carcinog. 2009 Oct;48(10):920-33 [19378291.001]
  • [Cites] Cancer Lett. 2009 Nov 28;285(2):127-33 [19477063.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):8958-66 [19903839.001]
  • [Cites] Anticancer Drugs. 2010 Feb;21(2):140-50 [20010425.001]
  • [Cites] Front Biosci (Schol Ed). 2010;2:697-717 [20036978.001]
  • [Cites] Indian J Cancer. 2010 Jan-Mar;47(1):53-8 [20071791.001]
  • [Cites] AAPS J. 2009 Dec;11(4):710-27 [19859815.001]
  • [Cites] J Ethnopharmacol. 2010 Feb 3;127(2):515-20 [19833188.001]
  • [Cites] J Epidemiol. 2010;20(2):83-9 [20173308.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):293-308 [20107892.001]
  • [Cites] Lymphat Res Biol. 2010 Mar;8(1):89-98 [20235891.001]
  • [Cites] Carcinogenesis. 2010 Apr;31(4):719-28 [20110283.001]
  • [Cites] Drug Test Anal. 2009 Jan;1(1):14-21 [20355154.001]
  • [Cites] J Agric Food Chem. 2010 Apr 28;58(8):4681-92 [20334341.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):277-84 [20496536.001]
  • [Cites] Biol Pharm Bull. 2010;33(7):1095-100 [20606295.001]
  • [Cites] Breast Cancer Res Treat. 2010 Aug;122(3):777-85 [19898931.001]
  • [Cites] Annu Rev Nutr. 2010 Aug 21;30:173-99 [20420526.001]
  • [Cites] Support Care Cancer. 2011 Apr;19(4):521-9 [20336329.001]
  • [Cites] Invest New Drugs. 2011 Aug;29(4):694-9 [20107864.001]
  • [Cites] Oncol Rep. 2010 Sep;24(3):747-57 [20664983.001]
  • (PMID = 20714787.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096694; United States / NIGMS NIH HHS / GM / T32 GM008716; United States / NCI NIH HHS / CA / R01CA96694
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS387858; NLM/ PMC3388613
  •  go-up   go-down


5. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%).
  • API were more likely to be diagnosed with regional or distant stage disease than were other racial/ethnic groups (27.5% and 11.8%, respectively).
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • A higher proportion of API were diagnosed at regional/distant stage.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


6. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • There is evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer, with early reports of an increasing role in outcome prognostication in a number of tumours.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • The stage determined by CIm and the proposed management plan were prospectively recorded and changes in stage and management as a result of FDG-PET assessed.
  • Kaplan-Meier survival analysis was used to estimate survival for the whole cohort and by FDG-PET and CIm stage.
  • The tumour-stage group was changed in 23% (14 out of 61) as a result of FDG-PET (15% up-staged, 8% down-staged).
  • Fourteen percent of T1 patients (3 out of 22), 42% of T2 patients (10 out of 24) and 40% of T3-4 patients (6 out of 15) assessed using CIm, had a change in their nodal or metastatic stage following FDG-PET.
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


7. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
  • Wide local excision is the mainstay of treatment for early stage tumors as it preserves continence and obtains adequate local control.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


8. Tournier-Rangeard L, Peiffert D, Lafond C, Mege A, Metayer Y, Marchesi V, Buchheit I, Uwer L, Conroy T, Kaminsky MC: [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]. Cancer Radiother; 2007 Jun;11(4):169-77
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation].
  • [Transliterated title] Résultats à long terme et facteurs pronostiques des carcinomes épidermoïdes du canal anal traités par irradiation.
  • PURPOSE: To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution.
  • Forty-three pts were stage I, 154 stage II, 31 stage IIIA and 53 stage IIIB.
  • Five-years-LRC were 71.5% (88% for stage I, 69% for stage II, 77%, for stage IIIA and 60% for stage IIIB).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400501.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Rakoto-Ratsimba HN, Rakototiana AF, Rakotosamimanana J, Ranaivozanany A: [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case]. Ann Chir; 2006 Nov;131(9):564-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case].
  • [Transliterated title] Fistule périanale révélatrice d'un adénocarcinome du canal anal. A propos d'une observation.
  • Anal adenocarcinoma revealed by a fistula-in-ano occurs rarely.
  • Symptomatology has no specificity and the diagnosis is often late, in an advanced stage of the sickness.
  • Recurrent or non recurrent fistula-in-ano requires multiple biopsies for pathology analysis in order to screen a related cancer.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Anus Neoplasms / complications. Anus Neoplasms / diagnosis. Rectal Fistula / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712770.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


10. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • The T-stage according to the 2001 UICC classification were: 2 T1, 26 T2, 25 T3, and 7 T4.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Hatfield P, Cooper R, Sebag-Montefiore D: Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):419-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
  • PURPOSE: To report the results of patients with early-stage anal cancer treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
  • All were considered to have Stage N0 disease radiologically.
  • CONCLUSION: The results of our study have shown that for patients with anal carcinoma who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Allison RR, Sheng C, Cuenca R, Bagnato VS, Austerlitz C, Sibata CH: Photodynamic therapy for anal cancer. Photodiagnosis Photodyn Ther; 2010 Jun;7(2):115-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for anal cancer.
  • Invasive anal cancers are generally successfully treated by combined chemotherapy with radiation therapy (XRT).
  • We examined the treatment and outcome of Photofrin based photodynamic therapy (PDT) in a cohort of patients with anal cancer who failed locally despite chemo-radiation (N=6) and two patients with positive margins of resection after excision of small T(1) squamous cell anal cancers who refused further surgery or chemo-radiation.
  • All patients completed PDT without incident and all have maintained local control of disease in the anal region for the length of follow up (18-48 months).
  • PDT may serve as a new means to salvage local failures and perhaps could be employed as a primary treatment modality in select patients with early stage of disease.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20510306.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  • [Number-of-references] 22
  •  go-up   go-down


13. Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE: Anal carcinoma in mid-Norway 1970-2000. Acta Oncol; 2007;46(7):1019-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in mid-Norway 1970-2000.
  • The treatment of anal carcinoma changed from surgery to chemoradiotherapy 20-25 years ago.
  • The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for anal carcinoma.
  • The study includes all 111 patients with anal carcinoma diagnosed between 1970 and 2000 in mid-Norway.
  • Stage, age and treatment were all significant indicators of survival in uni- and multivariable analysis.
  • Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the anal sphincter.
  • The change of strategy for anal cancer treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882558.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


14. Ficari F, Fazi M, Garcea A, Nesi G, Tonelli F: Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula. Suppl Tumori; 2005 May-Jun;4(3):S31
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula.
  • This paper reports six patients with perianal Crohn's disease (CD), who developed anal cancer in chronic anal fistulas.
  • Tumors have been often diagnosed at an advanced stage and had a worse prognosis than cancers arising in the general population as tumor symptoms may mimic symptoms of CD, resulting in delay in diagnosis.
  • Patients with perianal CD should undergo a careful surveillance program for ano-rectal carcinoma, including routine biopsy of any suspected lesion.
  • [MeSH-major] Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / complications

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437885.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Gavioli M, Losi L, Luppi G, Iacchetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G: Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):370-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
  • PURPOSE: To assess the frequency and magnitude of changes in lower rectal cancer resulting from preoperative therapy and its impact on sphincter-saving surgery.
  • Preoperative therapy can increase the rate of preserving surgery by shrinking the tumor and enhancing its distance from the anal sphincter.
  • METHODS AND MATERIALS: A total of 98 cases of locally advanced cancer of the lower rectum (90 Stage uT3-T4N0-N+ and 8 uT2N+M0) that had undergone preoperative therapy were studied by endorectal ultrasonography.
  • The maximal size of the tumor and its distance from the anal sphincter were measured in millimeters before and after preoperative therapy.
  • The distance between the tumor and the anal sphincter increased in 60.2% of cases.
  • It was possible in nearly 30% of patients in whom the cancer had reached the anal sphincter before the preoperative therapy.
  • CONCLUSION: The results of our study have shown that in very low rectal cancer, preoperative therapy causes tumor downsizing in >80% of cases and in more than one-half enhances the distance between the tumor and anal sphincter.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Avallone A, Delrio P, Di Gennaro E, Pecori B, Aloi L, Tatangelo F, Petrillo A, Budillon A, Caracò C, Sandomenico C, Comella P: Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):e14546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts).
  • According to the Simon's two-stage design, assuming a hypothesis of a 50% TRG1 (α=0.05, β=0.20), at least 6/16 TRG1 should be obtained to continue pts accrual in every schedule.
  • METHODS: Inclusion criteria were: cT4, cN+, cT3(<5 cm from the anal verge and/or +ve CRM), resectable M1.
  • Changes of circulating endothelial cells (CECs)assessed by flow cytometry in 17 (7 A; 10 B) pts, and glucose metabolism evaluated by FDG-PET in 27 (15 A; 12 B) pts after 1st c of CT were used as surrogate markers of tumor response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • Interestingly, only 1 of 8 primary cerebral lymphomas has been reported after 2001.
  • Anal carcinomas and Hodgkin's lymphomas in particular were markedly more prevalent in our HIV-positive cohort compared to published reports of the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH: Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol; 2009 May 20;27(15_suppl):4116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal.
  • : 4116 Background: Definitive therapy for squamous cell carcinoma (SCC) of the anal canal consists of external beam radiotherapy with concurrent 5-fluorouracil and mitomycin C or cisplatin.
  • The purpose of this study was to evaluate the tolerability and efficacy of XELOX-XRT as definitive treatment for anal cancer.
  • METHODS: Patients with histologically proven SCC of the anal canal, AJCC Stage II-IIIB (T<sub>2-4</sub> or N+M<sub>0</sub>), ECOG PS 0-1, HIV<sup>-</sup>, and no prior therapy were eligible for XELOX-based chemoradiotherapy.
  • Therefore, the chemotherapy schedule was modified and only 1 of 9 patients in Group 2 developed grade 3 diarrhea.
  • CONCLUSIONS: The combination of capecitabine, oxaliplatin, and radiation therapy (XELOX-XRT) is effective for locally advanced squamous cell carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma.
  • : e15108 Background: Preoperative concomitant chemoradiotherapy has shown to improve local control and sphincter preservation with decreased acute toxicity compared with postoperative treatment in locally advanced rectal carcinoma.
  • Secondary endpoint was sphincter preservation and toxicity Methods: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Clinical stage (determined by CT or RMI): T3: 66.6% and T4: 33.3%.
  • Tumor location (from anal verge): < 6 cm in 10pts, >6 cm in 5pts.
  • Main adverse effects (NCI-CTC): diarrhea G3-4: 14.2%, sensitive peripheral neurotoxicity G1: 26.6%, nausea/vomiting G3-4: 11%, Anemia G3-4: 7.1%, neutropenia G3-4: 14.2% Conclusions: Preliminary results show that preoperative concomitant chemoradiotherapy with oxaliplatin and 5FU-folinic acid is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Lobato LF, Stocchi L, da Luz Moreira A, Kalady M, Dietz D, Geisler D, Lavery I, Fazio V: Effect of downstaging without complete pathologic response after neoadjuvant treatment on cancer outcomes for cIII and cII rectal cancers. J Clin Oncol; 2009 May 20;27(15_suppl):4108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of downstaging without complete pathologic response after neoadjuvant treatment on cancer outcomes for cIII and cII rectal cancers.
  • : 4108 Background: Neoadjuvant chemoradiation followed by surgery is standard of care for locally advanced rectal cancer.
  • The aim of this study was to evaluate whether downstaging impacts prognosis in patients with cII vs. cIII rectal cancer.
  • METHODS: We identified from our colorectal cancer database 233 patients with primary cII and cIII rectal cancer staged by CT and ERUS/MRI who received 5FU-based chemoradiation followed by R0 surgery after a median interval of 7 weeks during 1997-2007.
  • Compared among the remaining 175 patients pathologic downstaging (cII to ypI, cIII to ypII or ypI) vs. No pathologic downstaging (c stage ≤ yp stage).
  • Patients with cII vs. cIII stage were statistically comparable regarding demographics, chemoradiation regimen, interval to surgery after neoadjuvant treatment, tumor distance from anal verge, operations performed and follow-up.
  • The incidence of downstaging was increased in stage cIII vs. cII patients (68% vs. 21%, p <0.001).
  • With the exception of local recurrence rates, downstaging resulted in significantly improved cancer outcomes for cIII but not cII ( Table ).
  • CONCLUSIONS: Downstaging without pCR is a significant prognostic factor for patients with stage cIII rectal cancer.
  • A larger sample size is required to confirm lack of downstaging benefits in stage cII.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Larbaoui B: Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma.
  • : e15134 Background: Preoperative concomitant chemoradiotherapy has shown to improve local control and sphincter preservation with decreased acute toxicity compared with postoperative treatment in locally advanced rectal carcinoma.
  • METHODS: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Clinical stage (determined by CT or RMI): T3: 70% and T4: 30%.
  • Tumor location (from anal verge): < 6 cm in 8pts, >6 cm in 7pts.
  • CONCLUSIONS: Preliminary results show that preoperative concomitant chemoradiotherapy with Capecitabine is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Pinto C, Di Fabio F, Maiello E, Di Tullio P, Pini S, Aschele C, Garufi C, Bochicchio A, Pinotti G, Latiano T, Martoni A: Phase II study of preoperative panitumumab, 5-fluorouracil, and oxaliplatin with concurrent radiotherapy in locally advanced rectal cancer: Preliminary safety results (StarPan /STAR-02 Study). J Clin Oncol; 2009 May 20;27(15_suppl):4110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of preoperative panitumumab, 5-fluorouracil, and oxaliplatin with concurrent radiotherapy in locally advanced rectal cancer: Preliminary safety results (StarPan /STAR-02 Study).
  • : 4110 Background: The aim of this phase II study is to assess the activity of preoperative external radiotherapy combined with panitumumab, oxaliplatin and 5-fluorouracil in locally advanced rectal cancer patients (pts).
  • METHODS: Pts entering the study had histologically-proven rectal adenocarcinoma, either uT3N+ or T4 N-/+ stage, with location <12 cm from the anal margin.
  • Radiotherapy was delivered up to a dose of 50.4 Gy in daily fractions of 1.8 Gy.
  • The characteristics of 29 pts were: males 19 (65.5%) and females 10 (34.5%); median age 58 years (range 39-78); median Karnofsky PS 100 (range 70-100); stage: uT3N+ 22 (75.9%), uT4N- 3 (10.3%), uT4N+ 4 (13.8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961230.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kazmi SS, Azfar M, Syed AA, Yusuf MA: Oxaliplatin-based neoadjuvant chemoradiation for locally advanced rectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-based neoadjuvant chemoradiation for locally advanced rectal cancer.
  • : e15102 Background: Preoperative chemoradiation improves local recurrence in patients with locally advanced rectal cancer<sup>1</sup>.
  • We report our experience with addition of Oxaliplatin to neoadjuvant chemoradiation for rectal cancer.
  • METHODS: For this retrospective study, thirty-six consecutive patients referred for neoadjuvant chemoradiation for rectal cancer between May 2007 and March 2008 were identified.
  • All patients had histologically proven adenocarcinoma, and were clinical stage T3/T4 or N+, except for one who was T2N0.
  • In patients with low rectal cancer (0-5cm from anal verge), 16/26(62%) underwent resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964336.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Velenik V, Ocvirk J, Oblak I, Anderluh F: Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial.
  • : e15029 Background: Preoperative chemoradiotherapy (CRT) with capecitabine is a treatment of choice for locally advanced rectal cancer.
  • The aim of this prospective, nonrandomized, open-label phase II study was to establish the efficacy and safety profile of cetuximab combined with capecitabine and concurrent RT for locally advanced resectable rectal cancer.
  • METHODS: Patients (pts) with stage II or III rectal cancer confirmed by MRI were treated with capecitabine 1250 mg/m<sup>2</sup> twice daily for 2 weeks.
  • The median tumor distance from anal verge was 6 (range: 1-11) cm.
  • The total sphincter preservation rate was 75.7%; in 17 pts whose tumors were located ≤5 cm of the anal verge, the rate was 53%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hammad N, Philip PA, Shields AF, Heilbrun LK, Venkatramanamoorthy R, El-Rayes BF: A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients.
  • : e15586 Background: Human immunodeficiency virus (HIV) infected patients (pts) are at increased risk for squamous cell carcinoma of the anal canal (SCCAC) and the incidence of SCCAC has increased in the era of HAART (highly active antiretroviral therapy).
  • The aim of this study is to describe the outcome, tolerability, and overall survival (OS) in pts with and without HIV infection treated at Karmanos Cancer Institute, at Wayne State University from 1991 to 2007.
  • We collected data regarding HIV status, demographics (age, gender, race), stage at diagnosis, treatment, response to treatment, toxicity, and survival.
  • HIV (+) pts had significantly better stage (p = 0.011) and less frequent reduced chemotherapy dose (p = 0.001).
  • CONCLUSIONS: HIV (+) pts had better stage, received standard chemotherapy dose more often, and had more frequent XRT dermatitis than HIV (-) pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962344.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • All 195 were treated with CRT- (50.4Gy in 28 fractions of 1.8 Gy with 5-fluorouracil (5-FU) + mitomycin (MMC).
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • RESULTS: Mean baseline SCCAg by cT and cN stage were: T1 93 (ng/dl), T2 300, T3 607, T4 882, N0 376, N+ 529 (correlation coeff: T: 0.47, N: 0.33, both p< 0.001).
  • CONCLUSIONS: There is a correlation between T and N stage and baseline SCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Young SC, Solomon MJ, Hruby G, Frizelle FA: Review of 120 anal cancer patients. Colorectal Dis; 2009 Nov;11(9):909-14
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of 120 anal cancer patients.
  • OBJECTIVE: Chemoradiotherapy is the mainstay of treatment for the majority of patients with anal cancer, with abdominoperineal resection reserved for salvage.
  • The purpose of this study was to evaluate our results after radiotherapy with or without chemotherapy, and/or surgery in terms of overall survival and colostomy free survival in patients with anal cancer.
  • METHOD: A review of patients diagnosed with anal cancer between 1991 and 2004 was performed.
  • The T stage distribution was T1 32, T2 44, T3 19, T4 17 and TX 8.
  • CONCLUSION: Chemoradiation is effective organ preserving treatment for anal cancer.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2009 Nov;11(9):914-6 [19832863.001]
  • (PMID = 19175651.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH: Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):794-800
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.
  • PURPOSE: To evaluate patterns of locoregional failure, and predictors of recurrence and survival in patients treated with chemoradiation for anal cancer.
  • METHODS AND MATERIALS: Between September 1992 and August 2004, 167 patients with nonmetastatic squamous cell anal carcinoma were treated with definitive chemoradiation.
  • Multivariate analysis showed that higher T stage and N stage independently predicted for a higher rate of locoregional failure; higher N stage and basaloid subtype independently predicted for a higher rate of distant metastasis; and higher N stage and positive human immunodeficiency virus status independently predicted for a lower rate of overall survival.
  • Among the patients who had locoregional failure, 18 (75%) had failure involving the anus or rectum, 5 (21%) had other pelvic recurrences, and 1 (4%) had inguinal recurrence.
  • The majority of locoregional failures involve the anus and rectum, whereas inguinal recurrences occur rarely.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant / mortality. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Radiotherapy, Adjuvant / mortality

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379452.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Crowley C, Winship AZ, Hawkins MA, Morris SL, Leslie MD: Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol); 2009 Jun;21(5):376-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
  • AIMS: Chemoradiation is the standard of care for the treatment of anal canal cancer, with surgery reserved for salvage.
  • MATERIALS AND METHODS: Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell anal canal cancer were treated with chemoradiation using one phase of treatment throughout.
  • CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation.
  • In future studies we would suggest that consideration is given as to whether omission of prophylactic inguinal nodal irradiation for early stage tumours should be explored.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lymphatic Irradiation. Radiation Injuries / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Female. Humans. Inguinal Canal. Male. Middle Aged. Patient Compliance. Pelvis. Radiation Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282157.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • Early stage disease, low T-score and absence of infiltration in adjacent organs were associated with a reduced need for colostomy in univariate analysis.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Dwyer MK, Gebski VJ, Jayamohan J: The bottom line: outcomes after conservation treatment in anal cancer. Australas Radiol; 2006 Feb;50(1):46-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bottom line: outcomes after conservation treatment in anal cancer.
  • At the Department of Radiation Oncology, Westmead Hospital, between 1980 and 2000, 60 patients with squamous cell carcinoma of anal canal or margin (including 15 with Stage IIIA or IIIB) were treated radically; 55 received chemoradiation (89% were prescribed mitomycin C and 5-fluorouracil).
  • Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499727.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ: Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg; 2009 Jul;13(7):1292-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.
  • PURPOSE: The staging of anal cancer is extremely important for therapy and prognosis.
  • METHODS: Forty-five anal cancer patients underwent endoscopic ultrasound and magnetic resonance imaging.
  • For six patients who were operated upon because of tumor progression, the results were evaluated against the histological tumor stage.
  • Cancer patients were correctly identified with 100% sensitivity (45/45) by endoscopic ultrasound and with 88.9% (40/45) sensitivity by magnetic resonance imaging.
  • In the six operated patients, T stage was correctly assessed in four of six patients by endoscopic ultrasound and in three of six patients by magnetic resonance imaging.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / ultrasonography. Endosonography. Magnetic Resonance Imaging. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / ultrasonography. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / ultrasonography. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365694.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Hauerstock D, Ennis RD, Grossbard M, Evans A: Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. Clin Colorectal Cancer; 2010 Oct;9(4):238-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
  • PURPOSE: The purpose of this retrospective study is to determine the results and the toxicity of concurrent chemoradiation for squamous cell carcinoma of the anal canal in HIV-positive patients treated at a single institution.
  • PATIENTS AND METHODS: HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries.
  • We reviewed hospital and treatment charts to gather data relating to demographics, HIV status including cluster of differentiation 4 (CD4) count and viral load, tumor stage, radiation and chemotherapy treatment, toxicity and local control, and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / complications. Radiotherapy, Conformal


35. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P: Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol; 2008 Dec;5(12):737-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
  • DIAGNOSIS: Stage IV M1b metastatic anal mucosal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Benzenesulfonates / therapeutic use. Melanoma / therapy. Pyridines / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936790.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


36. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors &lt; or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890590.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Mai SK, Welzel G, Hermann B, Bohrer M, Wenz F: Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity. Onkologie; 2008 May;31(5):251-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity.
  • BACKGROUND: This retrospective study evaluated the efficacy, prognostic factors, and toxicity of combined radiochemotherapy for anal cancer.
  • Tumor stage, nodal status, age, sex, tumor site, tumor resection, and radiation dose were analyzed for prognostic value.
  • Higher T category was associated with inferior prognosis for colostomy-free survival (p = 0.000), male sex for local control (p = 0.004) and diseasespecific survival (p = 0.002), and tumor site at the anal margin for local control (p = 0.03).
  • 4 of 7 patients with recurrent anal margin tumors had human papillomavirus (HPV)-related disease.
  • CONCLUSION: Combined radiochemotherapy for anal cancer is a highly effective therapy with pronounced acute and minor late toxicity.
  • In the case of higher T stage, male sex, and cancer at the anal margin, treatment intensification should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Anus Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Radiotherapy / mortality. Risk Assessment / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18497514.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


38. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis. Oncology (Williston Park); 2010 Apr 15;24(4):364-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis.
  • Although anal cancer is a rare disease, its incidence is increasing in men and women worldwide.
  • Anal cancer is generally preceded by high-grade anal intraepithelial neoplasia (HGAIN), which is most prevalent in human immunodeficiency virus (HIV)-positive men who have sex with men.
  • Meta-analysis suggests that 80% of anal cancers could be avoided by vaccination against HPV 16/18.
  • Nearly half of all patients with anal cancer present with rectal bleeding.
  • According to the Surveillance Epidemiology and End Results (SEER) database, 50% of patients with anal cancer have disease localized to the anus, 29% have regional lymph node involvement or direct spread beyond the primary, and 12% have metastatic disease, while 9% have an unknown stage.
  • Clinical staging of anal carcinoma requires a digital rectal exam and a computed tomography scan of the chest, abdomen, and pelvis.
  • The 5-year relative survival rates are 80.1% for localized anal cancer, 60.7% for regional disease, and 29.4% for metastatic disease.
  • Part 2 of this two-part review will address the treatment of anal cancer, highlighting studies of chemoradiation.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Mass Screening

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464850.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


39. Barriger RB, Calley C, Cárdenes HR: Treatment of anal carcinoma in immune-compromised patients. Clin Transl Oncol; 2009 Sep;11(9):609-14
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anal carcinoma in immune-compromised patients.
  • This study was undertaken to evaluate local control (LC), overall survival (OS) and toxicity in immune-compromised patients with anal carcinoma treated with radiotherapy with or without chemotherapy.
  • METHODS: We identified 25 patients with anal carcinoma and human immunodeficiency virus (HIV) infection or history of solid-organ transplant on chronic medical immune-suppression.
  • AJCC T-stages were Tis (4%), T1 (8%), T2 (58%) and T3 (29%).
  • T-stage and CD4 level in HIV-positive patients predict for LC.
  • T-stage and TT predict for OS.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Immunocompromised Host

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776001.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


40. Kidd EA, Dehdashti F, Siegel BA, Grigsby PW: Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol; 2010 Jun;95(3):288-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis.
  • PURPOSE: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUV(max)) by positron emission tomography (PET) and its correlation with prognostic factors.
  • PATIENTS AND METHODS: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET.
  • The stage distribution included: 2 stage 0, 7 stage I, 49 stage II, 10 stage IIIA, 9 stage IIIB.
  • Patients with high anal tumor SUV(max) at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4months after completing therapy (p=0.0402).
  • CONCLUSIONS: SUV(max) is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20231040.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


41. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, Yamaguchi S, Kondo Y, Saito N, Kato T, Ohue M, Higashino M, Moriya Y, Colorectal Cancer Study Group of the Japan Clinical Oncology Group: Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol; 2009 Oct;14(5):416-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for anal squamous cell carcinoma in Japan.
  • BACKGROUND: In Western countries, chemoradiotherapy (CRT) is well established as the standard therapy for stages II/III anal squamous cell carcinoma (ASCC).
  • The Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG-CCSG) conducted a survey to determine the current therapeutic strategies for ASCC in Japan.
  • Detailed information was obtained for 55 subjects; 25 (45%) had stage II ASCC and 30 (55%) had stage III ASCC.
  • [MeSH-major] Anus Neoplasms / therapy. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / therapy. Digestive System Surgical Procedures

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856049.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Investigator] Kondo Y; Ohtsuka K; Shiiba K; Sato T; Yoshimi F; Kotake K; Sawada T; Mochizuki H; Konishi F; Saito N; Moriya Y; Masaki T; Aoki T; Takahashi K; Hasegawa H; Kenichi S; Sumiyama Y; Sato T; Akaike M; Kudo S; Yamada T; Munakata Y; Shigeski Y; Kato T; Maeda K; Koizumi K; Monden M; Ohue M; Higashino M; Tanigawa M; Fukunaga M; Kato T; Okamura S; Kimura H; Okajima M; Takakura N; Tanada M; Shirouzu K; Kitano S
  •  go-up   go-down


42. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg; 2005 May;92(5):605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
  • BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
  • METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
  • Increasing age (P < 0.001, Cox model), total radiation dose (P = 0.004) and tumour stage (P = 0.010) were independent predictors of local failure.
  • CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction.
  • By implication, these factors favour the centralization of treatment for this uncommon cancer to a multidisciplinary oncology team.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15739215.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


44. Jeffreys M, Rachet B, McDowell S, Habib AG, Lepage C, Coleman MP: Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer; 2006 Jul;42(10):1434-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival from rectal and anal cancers in England and Wales, 1986-2001.
  • The aim of this study was to investigate the effects of tumour and patient characteristics on trends in the survival of patients with cancer of the anus or rectum in England and Wales.
  • The results showed that 5-year relative survival was higher in women, younger patients and more affluent patients, and higher for anal cancer than rectal cancer.
  • The trend was more marked in younger and more affluent patients, and for adenocarcinoma and epidermoid carcinoma than for tumours with other morphology.
  • It is concluded that improvements in survival may reflect improvements in disease stage, diagnostic technique or treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anus Neoplasms / mortality. England / epidemiology. Female. Humans. Middle Aged. Survival Analysis. Wales / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600590.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Zakharash MP, Poĭda AI, Mel'nik VM: [Abdomino-anal resection in the treatment of low-ampullar cancer of the rectum]. Khirurgiia (Mosk); 2005;(4):52-6
Genetic Alliance. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abdomino-anal resection in the treatment of low-ampullar cancer of the rectum].
  • Surgical policy was developed for improvement of functional results and quality of life in patients operated on for low rectal cancer.
  • This policy includes choice of the method of sphincter-saving operation depending on the stage of the tumor, grade of malignancy, distance from a low edge of the tumor to dentate line.
  • Methods of prevention of ischemia and necrosis of brought down colonic transplant and anal incontinence were used.
  • This increased the number of sphincter-saving operations in low location of rectal cancer by 35%, reduced the rate of necrosis of intestinal transplant from 7 to 4.4%, saved continent function and improved significantly quality of life in 89.8% operated patients.
  • [MeSH-major] Anal Canal / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940181.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


46. Kiran RP, Pokala N, Rottoli M, Fazio VW: Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades. Am Surg; 2009 Feb;75(2):163-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades.
  • Chemoradiotherapy is the standard treatment for anal cancer.
  • From a prospective population-based database on radiation and surgical therapy, we compare outcomes for patients with anal cancer undergoing rectal resection after radiation with patients undergoing radiation alone.
  • Patients undergoing surgical resection of the rectum after initial radiation (SRT) for squamous cell carcinoma of the anus, anal canal, cloacogenic zone, and overlapping lesions of the rectum and anal canal from 1983 to 2002 were identified from the Surveillance, Epidemiology and End Results database.
  • SRT had more patients with regional stage of disease (66.7 vs 42.4%, P = 0.001).
  • For patients with localized stage, survival for SRT and RT was similar (105 vs 98 months, P = 0.7).
  • For patients with regional stage, survival for SRT and RT was similar (95 vs 83 months, P = 0.6).
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280811.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Chefo S, Tsodikov A: Stage-specific cancer incidence: an artificially mixed multinomial logit model. Stat Med; 2009 Jul 10;28(15):2054-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific cancer incidence: an artificially mixed multinomial logit model.
  • Early detection of prostate cancer using the prostate-specific antigen test led to a sharp spike in the incidence of the disease accompanied by an equally sharp improvement in patient prognoses as evaluated at the point of advanced diagnosis.
  • Observed outcomes represent age at diagnosis and stage, a categorical prognostic variable combining the actual stage and the grade of tumor.
  • The picture is summarized by the stage-specific cancer incidence that represents a joint survival-multinomial response regressed on factors affecting the unobserved history of the disease before diagnosis (mixture).
  • The model provides a causal link between the screening policy in the population and the stage-specific incidence.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] Stat Methods Med Res. 1992;1(3):317-37 [1341663.001]
  • [Cites] Am J Epidemiol. 1999 Oct 15;150(8):848-60 [10522656.001]
  • [Cites] Lifetime Data Anal. 2004 Dec;10(4):325-34 [15690988.001]
  • [Cites] Stat Med. 2006 Aug 30;25(16):2846-66 [16397859.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):981-90 [12096083.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 18;95(12):868-78 [12813170.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):603-13 [15475422.001]
  • [Cites] Cancer. 2007 May 1;109(9):1877-86 [17372918.001]
  • (PMID = 19452568.001).
  • [ISSN] 1097-0258
  • [Journal-full-title] Statistics in medicine
  • [ISO-abbreviation] Stat Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097414-08; United States / NCI NIH HHS / CA / U01 CA097414; United States / NCI NIH HHS / CA / U01 CA097414-08; United States / NCI NIH HHS / CA / U01 CA97414
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS137840; NLM/ PMC2779845
  •  go-up   go-down


48. Yokoyama Y, Nishimura Y, Yatsuoka T, Sakamoto H, Tanaka Y, Nishimura Y, Kurosumi M: [A case of anal metastasis from sigmoid colon cancer in a long-term survivor who had repeated local excisions]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2585-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anal metastasis from sigmoid colon cancer in a long-term survivor who had repeated local excisions].
  • A 72-year-old man underwent sigmoidectomy for sigmoid colon cancer in January 1999.
  • Histopathological examination revealed a moderately differentiated adenocarcinoma, tub 2, SS, ly2, v2, N1, H0, P0, M0, Stage IIIa, cur A.
  • In March 2001, he complained of an anal bleeding and underwent colonoscopy.
  • It showed a submucosal tumor 15 mm in diameter at the anal canal and the biopsy indicated a moderately differentiated adenocarcinoma.
  • This tumor was suspected of metastasis from sigmoid colon cancer and transanal resection was performed in May 2001.
  • Histopathological examination revealed a moderately differentiated adenocarcinoma, which was the same histological type as primary sigmoid colon cancer, tub 2, A, ly2, v2, RM0.
  • The diagnosis of anal metastasis was made on the basis of three points.
  • First, tumor was covered with anal epithelium.
  • Thirdly, there were no findings of other primary anal cancer.
  • By removing anal canal metastases twice, inguinal lymph node metastases three times and lung metastases in each time, he survived for 11 years after a primary surgery.
  • We reported here because it was a very interesting and rare case that the patient was cancer-free after surgeries as many as seven times.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Anus Neoplasms / secondary. Anus Neoplasms / surgery. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224647.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Lefevre JH, Parc Y, Kernéis S, Shields C, Touboul E, Chaouat M, Tiret E: Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg; 2009 Nov;250(5):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing.
  • OBJECTIVES: To evaluate the results of a vertical rectus abdominis myocutaneus (VRAM) flap after abdomino-perineal resection (APR) for anal cancer (AC).
  • The groups (VRAM vs. No VRAM) differed in age at surgery (56.3 vs. 62.1; P = 0.0263); administration of chemotherapy in addition to radiotherapy (81% vs. 59%; P = 0.0218); and stage (ypT3-T4 67.6% vs. 38.4%; P = 0.0394).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Postoperative Complications. Surgical Flaps. Wound Healing

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801930.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U Jr, Silva E Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J: Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg; 2005 Jan;9(1):90-9; discussion 99-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
  • Neoadjuvant chemoradiation treatment (CRT) has resulted in significant tumor downstaging and improved local disease control for distal rectal cancer.
  • The purpose of the present study was to determine the correlation between final stage and survival in these patients regardless of initial disease stage.
  • Two hundred sixty patients with distal (0-7 cm from anal verge) rectal adenocarcinoma considered resectable were treated by neoadjuvant CRT with 5-FU and leucovorin plus 5040 cGy.
  • Overall survival and disease-free survival were compared according to Kaplan-Meier curves and log-rank tests according to final stage.
  • Seventy-one patients (28%) showed complete clinical response (clinical stage 0).
  • In 22 of these patients (9%), pathologic examination revealed pT0 N0 M0 (stage p0), 59 patients (22%) had stage I, 68 patients (26%) had stage II, and 40 patients (15%) had stage III disease.
  • Overall survival rates were significantly higher in stage c0 (P=0.01) compared with stage p0.
  • Disease-free survival rate showed better results in stage c0, but the results were not significant.
  • Five-year overall and disease-free survival rates were 97.7% and 84% (stage 0); 94% and 74% (stage I); 83% and 50% (stage II); and 56% and 28% (stage III), respectively.
  • Cancer-related overall and disease-free survival may be correlated to final pathologic staging following neoadjuvant CRT for distal rectal cancer.
  • Also, stage 0 is significantly associated with improved outcome.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15623449.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


52. Tixier H, Fraisse J, Chauffert B, Mayer F, Causeret S, Loustalot C, Deville C, Bonnetain F, Sagot P, Douvier S, Cuisenier J: Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer. Arch Gynecol Obstet; 2010 Mar;281(3):505-10
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer.
  • PURPOSE: The main aim of this study was to show the interest of pelvic posterior exenteration to obtain complete resection of the tumor in case of invasion of the rectum by contiguity in advanced-stage ovarian cancer.
  • METHODS: It is a multicentric, retrospective study of a series of 41 patients, who underwent posterior pelvectomy for advanced-stage ovarian cancer, over a period of 18 years, from July 1989 to July 2007.
  • In 34 patients (34/41), digestive continuity with satisfactory anal sphincter function was restored immediately or in the short term.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847452.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


53. Kim DW, Lim SB, Kim DY, Kim TH, Jung KH, Kim DH, Chang HJ, Sohn DK, Hong CW, Choi HS, Jeong SY, Park JG: Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge. Eur J Surg Oncol; 2006 Mar;32(2):162-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.
  • AIMS: To evaluate whether pre-operative chemo-radiotherapy (CRT) improves the sphincter preservation rate for distal rectal cancers within 3 cm of the anal verge.
  • METHODS: Between January 2001 and December 2004, 49 patients underwent surgery with or without pre-operative CRT for primary rectal adenocarcinoma within 3 cm of the anal verge.
  • Clinical data were retrospectively reviewed, including stage workups, surgical records and pathology records to determine sphincter preservation rate and the factors influencing sphincter preservation.
  • RESULTS: Of 49 patients with rectal tumours within 3 cm of the anal verge, 31 underwent pre-operative CRT followed by surgery (CRT group), and 18 underwent surgery alone (non-CRT group).
  • CONCLUSION: We could observe that sphincter preservation was improved in CRT group with statistical significance when compared to non-CRT group in our study patients with rectal cancer within 3 cm of the anal verge.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Anal Canal / drug effects. Anal Canal / radiation effects. Neoadjuvant Therapy. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289718.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol; 2005 Feb;12(2):111-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
  • BACKGROUND: We investigated the relationship between pathologic T-stage and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical stage II to III rectal carcinoma.
  • METHODS: The records of consecutive patients with clinical stage II to III carcinoma of the mid or low rectum who underwent surgery after CRT were reviewed.
  • Indications for preoperative CRT were cancer up to 11 cm from the anal verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis stage II or III.
  • The pretreatment tumor-node-metastasis stage was as follows: I, n = 1; II, n = 96; and III, n = 138.
  • According to the pT stage, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
  • On considering pT stage alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
  • CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical stage II to III mid or low rectal cancer, the risk of nodal metastases is very low.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):95-7 [15827785.001]
  • (PMID = 15827790.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


55. Albright JB, Bonatti H, Stauffer J, Dickson RC, Nguyen J, Harnois D, Jeanpierre C, Hinder R, Steers J, Chua H, Aranda-Michel J: Colorectal and anal neoplasms following liver transplantation. Colorectal Dis; 2010 Jul;12(7):657-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal and anal neoplasms following liver transplantation.
  • OBJECTIVE: Liver transplantation (LT) is the treatment of choice for end-stage liver disease.
  • Data on neoplasms of the colon, rectum and anus in LT are limited.
  • METHOD: A retrospective evaluation of the incidence and clinical course of colorectal and anal malignancies and colonic polyps in a series of 467 consecutive LTs in 402 individuals between 1998 and 2001 was performed.
  • RESULTS: During a median follow up of 5.2 years, three colon adenocarcinomas, one EBV associated cecal posttransplant lymphoproliferative tumour and two HPV associated anal tumours were identified.
  • No patient died from colorectal/anal malignancy.
  • Viral-associated malignancies, including post-transplant lymphoproliferative disorders and anal cancer, are important entities in the LT population suggesting that complete screening of the colon, rectum and anus including pre-LT and post-LT colonoscopy should be utilized.
  • [MeSH-major] Anus Neoplasms / epidemiology. Colonic Neoplasms / epidemiology. Immunosuppression / adverse effects. Liver Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508543.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Oblak I, Petric P, Anderluh F, Velenik V, Hudej R, Fras AP: Anal cancer chemoirradiation with curative intent - a single institution experience. Neoplasma; 2009;56(2):150-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer chemoirradiation with curative intent - a single institution experience.
  • Results of radiochemotherapy in 50 patients with squamous cell carcinoma of the anal canal, treated with radical radiochemotherapy between January 2003 and September 2007, at the Institute of Oncology Ljubljana are presented.
  • In the multivariate analysis, nodal stage was identified as an independent prognostic factor for LRC, DSS and CFS and application of Mitomycin C for OS.
  • Late anal stenosis, chronic ulceration and grade 2-3 incontinence developed in 3 (6 %), 2 (4 %) and 5 (10 %) of colostomy-free survivors, respectively.
  • </p> KEYWORDS: anal cancer, radiochemotherapy, survival, toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239330.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


57. Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, Oka T, Gong Y, Guo R, Inada H, Nawa K, Kojika M, Suga Y, Ohira T, Mukai K, Kato H: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer; 2008 Feb 12;98(3):596-603
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
  • Although postoperative adjuvant chemotherapy (PAC) with uracil-tegafur significantly improves the prognosis of patients with stage I lung adenocarcinoma, subset analysis has revealed that only 11.5% of patients with stage IB derive actual benefit from such therapy.
  • We performed comprehensive protein analysis of 24 surgically resected specimens of stage I adenocarcinoma using liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by bioinformatical investigations to identify protein molecules.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 May 18;105(4):425-31 [11371340.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61 [14519751.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):999-1012 [15195114.001]
  • [Cites] J Pathol. 1996 Oct;180(2):175-80 [8976877.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 1):1643-54 [8978829.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):483-95 [9033265.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2085-8 [9748123.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Proteomics. 2005 Mar;5(4):856-64 [15668996.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Tumour Biol. 2005 May-Jun;26(3):153-7 [15970650.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):677-80 [16243835.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Gan. 1979 Apr;70(2):209-14 [381088.001]
  • [Cites] Gan. 1979 Jun;70(3):353-9 [467897.001]
  • [Cites] Oncogene. 1993 Apr;8(4):999-1008 [8455951.001]
  • [Cites] Am J Clin Pathol. 1994 Aug;102(2):171-5 [8042584.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • (PMID = 18212748.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vimentin; 1548R74NSZ / Tegafur; EC 3.6.1.- / Nonmuscle Myosin Type IIA
  • [Other-IDs] NLM/ PMC2243141
  •  go-up   go-down


58. Chen YW, Yen SH, Chen SY, Huang PI, Shiau CY, Liu YM, Lin JK, Wang LW: Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol; 2007 Oct 1;96(5):374-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
  • BACKGROUND: To evaluate anus-preservation treatment for anal cancer.
  • METHODS: Review of 42 patients (24 M/18 F; median age, 70 years; range, 13-95) with stage I-IIIB disease (squamous cell carcinoma [SqCC], 33; adenocarcinoma, 9) who received curative radiotherapy between 1991 and 2004.
  • Five-year functional anus-preservation rate was 64%.
  • In multivariate analysis, OS was affected by performance status (P < 0.001), N stage (P = 0.009), and pathological type (P = 0.006).
  • Only N stage (P = 0.001) affected DFS.
  • CONCLUSION: With careful monitoring of toxicity, non-surgical anus-preservation treatment with good tumor control is feasible.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17492635.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ: Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):143-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
  • PURPOSE: Information is limited as to how we should treat invasive anal squamous cell carcinoma (SCC) in patients with chronic immunosuppression, since the majority of clinical studies to date have excluded such patients.
  • The objective of this study is to compare treatment outcomes in immunocompetent (IC) versus immunodeficient (ID) patients with invasive anal SCC treated similarly with combined modality therapy.
  • There were no significant differences in tumor size, T stage, N stage, chemotherapy doses, or radiation doses between the two groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203845.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hong J, Tang YQ: [Efficacy of local resection on lower rectal cancer of early stage: efficacy of report of 23 cases]. Ai Zheng; 2005 Jan;24(1):79-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of local resection on lower rectal cancer of early stage: efficacy of report of 23 cases].
  • BACKGROUND & OBJECTIVE: The trans-anal local excision for lower rectal cancer of early stage may achieve the same therapeutic effect as abdominal resection.
  • This study was to evaluate efficacy of local resection for lower rectal cancer of early stage.
  • METHODS: Records of 23 patients with lower rectal cancer of early stage received local excision from Feb.
  • RESULTS: Of the 23 patients,12 were adenocarcinoma, and 11 were canceration of adenoma; 17 with tumor of stage T0, and 6 with tumor of stage T1.
  • Three patients had local recurrence, 2 of 3 were salvaged by trans-anal local excision, and 1 of 3 was treated by abdominoperineal resection.
  • CONCLUSION: So long as carefully considering indications of trans-anal local excision in treating patients with lower rectal cancer of early stage, good efficacy may be achieved.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642206.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Morikawa A, Williams TY, Dirix L, Colpaert C, Goodman M, Lyles RH, Zhong D, Zhou W: Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer. Breast Cancer Res; 2005;7(6):R1051-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer.
  • INTRODUCTION: Identification of breast cancer patients at risk for postoperative distant relapse is an important clinical issue.
  • METHODS: Using 'counting alleles', a novel experimental method, we determined allelic status of chromosomes 8p and 18q in a case-control study with 65 early stage, node negative, invasive ductal carcinomas (IDCs).
  • CONCLUSION: Our finding suggests that differential allelic loss of chromosomes 8p and 18q may represent subtypes of early stage IDC with different tumor progression behaviors.
  • [MeSH-major] Allelic Imbalance. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 8 / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jan 31;415(6871):484-5 [11831227.001]
  • [Cites] Lancet. 2002 Jan 19;359(9302):219-25 [11812558.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3863-9 [12473601.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):50-4 [12490761.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Prostate. 2004 Sep 15;61(1):81-91 [15287096.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] J Mol Med (Berl). 1997 Jun;75(6):429-39 [9231883.001]
  • [Cites] Nat Biotechnol. 1998 Jan;16(1):49-53 [9447593.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1031-6 [9615760.001]
  • [Cites] Nat Biotechnol. 1996 Mar;14(3):303-8 [9630890.001]
  • [Cites] Genet Anal. 1999 Feb;14(5-6):151-6 [10084107.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Breast Cancer Res. 2004;6(6):229-39 [15535852.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):854-7 [10706093.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):305-10 [10861509.001]
  • [Cites] Nat Biotechnol. 2001 Jan;19(1):78-81 [11135558.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):818-22 [11221861.001]
  • [Cites] J Pathol. 2001 Apr;193(4):442-9 [11276002.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):65-72 [11790983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13647-52 [12370419.001]
  • (PMID = 16457686.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1410773
  •  go-up   go-down


63. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Kong AP, Kim J, Holt A, Konyalian V, Huynh R, Udani SM, Stamos MJ, Kumar RR: Selective treatment of rectal cancer with single-stage coloanal or ultralow colorectal anastomosis does not adversely affect morbidity and mortality. Int J Colorectal Dis; 2007 Aug;22(8):897-901
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective treatment of rectal cancer with single-stage coloanal or ultralow colorectal anastomosis does not adversely affect morbidity and mortality.
  • BACKGROUND AND AIMS: The surgical treatment of low rectal cancer commonly includes low pelvic anastomoses with coloanal or ultralow colorectal anastomoses.
  • MATERIALS AND METHODS: A retrospective chart review of 66 rectal cancer patients who underwent proctectomy and low pelvic anastomoses -- less than 6 cm from anal verge, with or without a diverting ostomy -- was undertaken.
  • RESULTS/FINDINGS: Forty-nine patients (78% preoperatively irradiated) were treated with a one-stage operation, whereas 17 (53% preoperatively irradiated) underwent reconstruction with proximal diversion.
  • The mean anastomotic height for patients with a single stage procedure was 3.8 cm above the anal verge versus 2.6 for patients with a two-stage procedure (p = 0.076).
  • With regard to anastomotic-associated complications for single stage versus two stage, complication rates were 8% versus 18%, respectively (p = 0.27).
  • INTERPRETATION/CONCLUSION: Low pelvic anastomoses in rectal cancer patients can be safely performed as a single-stage procedure, reserving the use of diversion for select cases.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colon / surgery. Digestive System Surgical Procedures / methods. Rectal Neoplasms / surgery. Rectum / surgery. Surgical Stomas

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361396.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Tiziani S, Lopes V, Günther UL: Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia; 2009 Mar;11(3):269-76, 4p following 269
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage diagnosis of oral cancer using 1H NMR-based metabolomics.
  • Oral cancer is the eighth most common cancer worldwide and represents a significant disease burden.
  • If detected at an early stage, survival from oral cancer is better than 90% at 5 years, whereas late stage disease survival is only 30%.
  • Therefore, there is an obvious clinical utility for novel metabolic markers that help to diagnose oral cancer at an early stage and to monitor treatment response.
  • In the current study, blood samples of oral cancer patients were analyzed using nuclear magnetic resonance spectroscopy to derive a metabolic signature for oral cancer.
  • Using multivariate chemometric analysis, we obtained an excellent discrimination between serum samples from cancer patients and from a control group and could also discriminate between different stages of disease.
  • The metabolic profile obtained for oral cancer is significant, even for early stage disease and relatively small tumors.
  • This suggests a systemic metabolic response to cancer, which bears great potential for early diagnosis.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Anal Chim Acta. 2008 Mar 3;610(1):80-8 [18267143.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Nov-Dec;21(10):1930-5 [11110549.001]
  • [Cites] Adv Enzyme Regul. 2002;42:131-41 [12123711.001]
  • [Cites] Head Neck. 2002 Aug;24(8):766-72 [12203802.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1015-24 [12569601.001]
  • [Cites] Analyst. 2003 Jan;128(1):32-6 [12572799.001]
  • [Cites] Analyst. 2003 Jul;128(7):814-8 [12894815.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):943-8 [14550295.001]
  • [Cites] Proc Natl Acad Sci U S A. 1965 Jun;53(6):1410-5 [5217643.001]
  • [Cites] J Natl Cancer Inst. 1981 Apr;66(4):653-8 [6939912.001]
  • [Cites] Surgery. 1984 Jun;95(6):730-8 [6427962.001]
  • [Cites] Annu Rev Nutr. 1990;10:107-32 [2200459.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):47-52 [1650241.001]
  • [Cites] Surgery. 1992 Mar;111(3):301-10 [1542855.001]
  • [Cites] Cancer. 1992 May 1;69(9):2343-8 [1562982.001]
  • [Cites] Surg Oncol. 1992 Aug;1(4):257-67 [1341259.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2150-9 [17332345.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1057-72 [9194433.001]
  • [Cites] NMR Biomed. 1998 Nov;11(7):360-9 [9859942.001]
  • [Cites] Anal Biochem. 2008 Jun 1;377(1):16-23 [18312846.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):782-8 [15499633.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1805-6 [15601632.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):167-78 [15644773.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):806-16 [15609302.001]
  • [Cites] J Magn Reson. 2005 May;174(1):97-109 [15809177.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):267-76 [15894488.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Sep;26(8):2108-13 [16155166.001]
  • [Cites] Oncology. 2005;69(3):246-55 [16127291.001]
  • [Cites] J Proteome Res. 2006 Apr;5(4):756-60 [16602681.001]
  • [Cites] NMR Biomed. 2006 Jun;19(4):504-12 [16763965.001]
  • [Cites] Med Hypotheses. 2006;67(5):1213-22 [16797873.001]
  • [Cites] MAGMA. 2006 Dec;19(6):281-96 [17171386.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Mar;65(3):452-6 [17307592.001]
  • [Cites] J Magn Reson Imaging. 2007 May;25(5):992-9 [17410583.001]
  • [Cites] NMR Biomed. 2007 Jun;20(4):401-12 [17149801.001]
  • [Cites] Am J Respir Crit Care Med. 2007 May 15;175(10):986-90 [17303796.001]
  • [Cites] BMC Bioinformatics. 2007;8:234 [17605789.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Jan;21(1):183-93 [10669248.001]
  • (PMID = 19242608.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2647729
  •  go-up   go-down


66. Kinney SR, Moser MT, Pascual M, Greally JM, Foster BA, Karpf AR: Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer. Mol Cell Biol; 2010 Sep;30(17):4159-74
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer.
  • Previous studies have shown that tumor progression in the transgenic adenocarcinoma of mouse prostate (TRAMP) model is characterized by global DNA hypomethylation initiated during early-stage disease and locus-specific DNA hypermethylation occurring predominantly in late-stage disease.
  • Here, we utilized Dnmt1 hypomorphic alleles to examine the role of Dnmt1 in normal prostate development and in prostate cancer in TRAMP.
  • Thus, Dnmt1 has tumor suppressor activity in early-stage prostate cancer, and oncogenic activity in late stage prostate cancer and metastasis.
  • Consistent with the biological phenotype, epigenomic studies revealed that TRAMP; Dnmt1 hypomorphic mice show dramatically reduced CpG island and promoter DNA hypermethylation in late-stage primary tumors compared to control mice.
  • Taken together, the data reveal a crucial role for Dnmt1 in prostate cancer and suggest that Dnmt1-targeted interventions may have utility specifically for advanced and/or metastatic prostate cancer.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] J Urol. 2009 Aug;182(2):756-61 [19539327.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):751-7 [11259619.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7500-6 [11096088.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 28;287(3):705-13 [11563853.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1296-9 [11888894.001]
  • [Cites] Mol Cell Biol. 2002 May;22(9):2906-17 [11940649.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5361-79 [12154399.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5496-503 [12154410.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Dev Biol. 2004 Apr 15;268(2):403-15 [15063176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(11):3389-93 [6203119.001]
  • [Cites] Cell. 1992 Jun 12;69(6):915-26 [1606615.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Cell. 1995 Apr 21;81(2):197-205 [7537636.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7327-35 [10523621.001]
  • [Cites] Acta Endocrinol (Copenh). 1965 May;49:145-54 [14277117.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13580-5 [16174748.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8635-9 [16204030.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6667-75 [16007164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):385-92 [16397253.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):682-92 [16423997.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1105-13 [16424047.001]
  • [Cites] Genome Res. 2006 Aug;16(8):1046-55 [16809668.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(19):7077-85 [16980612.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3089-103 [17085482.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11659-67 [17178860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2136-43 [17404097.001]
  • [Cites] Nucleic Acids Res. 2009 Jul;37(12):3829-39 [19386619.001]
  • [Cites] Prostate. 2009 Sep 1;69(12):1312-24 [19444856.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Sep 25;387(3):611-6 [19632198.001]
  • [Cites] Endocrinology. 2009 Sep;150(9):3991-4002 [19520778.001]
  • [Cites] Surg Oncol. 2009 Sep;18(3):203-12 [19398328.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Dec;2(12):1065-75 [19934341.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1742-57 [17512859.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Sep;46(9):796-804 [17534929.001]
  • [Cites] Anticancer Drugs. 2007 Nov;18(10):1157-64 [17893516.001]
  • [Cites] PLoS Genet. 2007 Oct;3(10):2023-36 [17967063.001]
  • [Cites] Mol Endocrinol. 2007 Dec;21(12):2855-63 [17636035.001]
  • [Cites] Curr Protoc Immunol. 2001 Nov;Chapter 20:Unit 20.5 [18432778.001]
  • [Cites] Bioinformatics. 2008 May 1;24(9):1161-7 [18353789.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4173-82 [18519676.001]
  • [Cites] Mol Cancer Res. 2008 Aug;6(8):1365-74 [18667590.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9358-66 [19010910.001]
  • [Cites] Gene. 2009 Feb 15;431(1-2):55-60 [19027835.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):240-5 [19002169.001]
  • [Cites] Cancer Sci. 2009 Jul;100(7):1186-91 [19432896.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • (PMID = 20584988.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R21CA128062; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R21 CA128062; United States / NCI NIH HHS / CA / R21 CA128062-02; United States / NCI NIH HHS / CA / CA128062-02; United States / NCI NIH HHS / CA / 5T32CA009072; United States / NCI NIH HHS / CA / T32 CA009072
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1
  • [Other-IDs] NLM/ PMC2937561
  •  go-up   go-down


67. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


68. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
  • BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.
  • Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.
  • RESULTS: PET/CT fused images led to change the stage in 5/27 cases (18.5%): 3 cases from N0 to N2 and 2 from M0 to M1 leading to change the treatment intent from curative to palliative in a case.Based on PET/CT imaging, GTV and CTV contours changed in 15/27 (55.6%) and in 10/27 cases (37.0%) respectively.
  • CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.
  • Clinical stage variation occurred in 18.5% of cases with change of treatment intent in 3.7%.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


69. Vuong T, Kopek N, Ducruet T, Portelance L, Faria S, Bahoric B, Devic S: Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys; 2007 Apr 1;67(5):1394-400
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy.
  • PURPOSE: To evaluate the clinical outcomes of three-dimensional conformal radiotherapy (3D-CRT) in patients with anal canal cancer, in terms of local control (LC), freedom from relapse (FFR), and overall survival (OS) rates, and to estimate long-term toxicity data.
  • RESULTS: No differences in stage and age distribution were observed between the two groups.
  • CONCLUSION: The use of 3D-CRT allows patients with anal canal cancer to complete radiation and chemotherapy without interruption for toxicity, with significant improvements in LC, FFR, and OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276620.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


70. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


72. Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ: Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1431-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
  • PURPOSE: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V(10) and PBM-V(20)) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy.
  • METHODS AND MATERIALS: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy.
  • RESULTS: Twenty patients (42%) had Stage T3-4 disease; 15 patients (31%) were node positive.
  • CONCLUSION: This analysis supports the hypothesis that increased low-dose radiation to PBM is associated with acute HT during chemoradiotherapy for anal cancer.
  • Techniques to limit bone marrow irradiation may reduce HT in anal cancer patients.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Bone Marrow / radiation effects

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996390.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


73. Crump KS, Subramaniam RP, Van Landingham CB: A numerical solution to the nonhomogeneous two-stage MVK model of cancer. Risk Anal; 2005 Aug;25(4):921-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A numerical solution to the nonhomogeneous two-stage MVK model of cancer.
  • In this article, we describe a straightforward method for solving the probability of at least one malignant cell by time t, and the associated hazard function, in the general (i.e., nonhomogeneous) two-stage Moolgavkar-Venzon-Knudson (MVK) model of cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16268939.001).
  • [ISSN] 0272-4332
  • [Journal-full-title] Risk analysis : an official publication of the Society for Risk Analysis
  • [ISO-abbreviation] Risk Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


74. Mathews C, Caperna J, Cachay ER, Cosman B: Early impact and performance characteristics of an established anal dysplasia screening program: program evaluation considerations. Open AIDS J; 2007;1:11-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early impact and performance characteristics of an established anal dysplasia screening program: program evaluation considerations.
  • BACKGROUND: Screening for invasive anal cancer and its precursors is being increasingly advocated as a response to increasing incidence among HIV-infected persons.
  • (1) to estimate incidence of and mortality from invasive anal cancer (IAC) before (1995-2000) and after (2001-2005) screening program implementation and (2) to examine potential screening program quality indicators.
  • (2) stage shift to IAC of more favorable prognosis is a reasonable screening goal;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):186-92 [8463044.001]
  • [Cites] Health Qual Life Outcomes. 2007;5:3 [17210071.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50 [16972138.001]
  • [Cites] Surg Today. 2006;36(10):885-91 [16998682.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Am J Obstet Gynecol. 2006 Mar;194(3):704-10 [16522401.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Mar;57(3):215-24 [16371251.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Sex Health. 2004;1(3):137-40 [16335300.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Sex Transm Infect. 2005 Oct;81(5):415-8 [16199742.001]
  • [Cites] Acta Cytol. 2005 Jul-Aug;49(4):405-15 [16124170.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] Diagn Cytopathol. 2005 Sep;33(3):152-6 [16078257.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):226-32 [16054967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Fam Med. 2005 May;37(5):360-3 [15883903.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] J Med Screen. 2005;12(1):12-9 [15825234.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5 [15630846.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Med J Aust. 1999 Mar 15;170(6):255-8 [10212646.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):252-8 [10037103.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1598-601 [9893635.001]
  • [Cites] Obstet Gynecol. 1998 Oct;92(4 Pt 2):727-35 [9764690.001]
  • [Cites] Fam Med. 1998 May;30(5):350-5 [9597533.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 May;14(2):117-28 [1530116.001]
  • [Cites] J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S14-6 [2231057.001]
  • [Cites] Am J Epidemiol. 1988 Dec;128(6):1185-97 [3057878.001]
  • [Cites] IARC Sci Publ. 1986;(76):185-98 [3570404.001]
  • [Cites] IARC Sci Publ. 1985;(66):45-63 [4093187.001]
  • [Cites] Am J Public Health. 1978 Feb;68(2):125-34 [626255.001]
  • [Cites] Prev Med. 1977 Dec;6(4):487-99 [600908.001]
  • [Cites] Cancer. 2004 Sep 1;101(5 Suppl):1131-45 [15316907.001]
  • [Cites] Prev Med. 2004 Aug;39(2):404-12 [15226053.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2003 Jul 1;188(1):128-36 [12825181.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):137-44 [12821354.001]
  • [Cites] Colorectal Dis. 2003 May;5(3):206-13 [12780879.001]
  • [Cites] Top HIV Med. 2003 Mar-Apr;11(2):45-9 [12717041.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Pt 2):435-78 [12617574.001]
  • [Cites] Obstet Gynecol. 2003 Jan;101(1):29-37 [12517642.001]
  • [Cites] Epidemiology. 2002 Nov;13(6):713-7 [12410014.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Int J Colorectal Dis. 2002 Jul;17(4):203-15 [12073068.001]
  • [Cites] Am J Obstet Gynecol. 2001 Aug;185(2):507-13 [11518918.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Dec 2;144(49):2345-8 [11129969.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1589-97 [17942872.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]
  • [Cites] BMJ. 1998 Aug 1;317(7154):307-12 [9685274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):619-26 [7827594.001]
  • [Cites] Sex Transm Dis. 2007 Mar;34(3):170-3 [16837830.001]
  • (PMID = 18776956.001).
  • [ISSN] 1874-6136
  • [Journal-full-title] The open AIDS journal
  • [ISO-abbreviation] Open AIDS J
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI067039-02; United States / NIAID NIH HHS / AI / R24 AI067039-02; United States / NIAID NIH HHS / AI / R24 AI067039; United States / NIAID NIH HHS / AI / P30 AI036214; United States / NIAID NIH HHS / AI / P30 AI036214-09A1
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Anal dysplasia / HIV. / screening
  •  go-up   go-down


75. Piperkova E, Raphael B, Altinyay M, Castellon I, Libes R, Sandella N, Abdel-Dayem H: Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON; 2006 Oct-Dec;11(4):523-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
  • Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCAC) and survival depends on the treatment strategy.
  • We present a patient with SCAC in whom, according to PET/CT findings, the initial stage was changed from II (T2N0M0) to III A (T2N2M0).
  • Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma.
  • The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309188.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


76. Choi DJ, Kim SH, Lee PJ, Kim J, Woo SU: Single-stage totally robotic dissection for rectal cancer surgery: technique and short-term outcome in 50 consecutive patients. Dis Colon Rectum; 2009 Nov;52(11):1824-30
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-stage totally robotic dissection for rectal cancer surgery: technique and short-term outcome in 50 consecutive patients.
  • PURPOSE: To overcome the pitfalls of laparoscopy, a robotic system has been introduced in rectal cancer surgery.
  • Therefore, we describe our technique of applying the robotic system during all of the steps of dissection in rectal cancer surgery and the short-term outcome.
  • METHODS: Prospectively collected data were reviewed from 50 consecutive patients who underwent single-stage, totally robotic dissection for rectal cancer resection between July 2007 and June 2008.
  • The mean distance from the anal verge to the tumor margin was 7.3 (range, 2-13) cm.
  • CONCLUSIONS: Single-stage robotic dissection for rectal cancer surgery is feasible, and its short-term outcome is acceptable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966627.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 2: current treatment standards and future directions. Oncology (Williston Park); 2010 Apr 30;24(5):417-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 2: current treatment standards and future directions.
  • The treatment of anal squamous cell cancer with definitive chemoradiation is the gold-standard therapy for localized anal cancer, primarily because of its sphincter-saving and colostomy-sparing potential.
  • In the concluding part of this review, we consider the data on chemoradiation with 5-FU/mitomycin vs radiation alone, chemoradiation with 5-FU/mitomycin vs chemoradiation with 5-FU alone, neoadjuvant chemotherapy with cisplatin/5-FU followed by cisplatin/5-FU plus radiation vs mitomycin/5-FU plus radiation, the addition of induction or maintenance chemotherapy to chemoradiation, the effect of overall treatment time on tumor control, whether chemotherapy can be eliminated for early-stage anal cancer, and the impact of human immunodeficiency virus infection on treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Apr 30;24(5):427-30 [20480742.001]
  • [CommentIn] Oncology (Williston Park). 2010 Apr 30;24(5):424-7 [20480741.001]
  • (PMID = 20480740.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 52
  •  go-up   go-down


78. Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MA: A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum; 2009 Aug;52(8):1375-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A twenty-year experience with adenocarcinoma of the anal canal.
  • PURPOSE: Adenocarcinoma of the anal canal is a rare malignancy with limited data regarding treatment and outcomes.
  • The purpose of this study is to evaluate disease control and survival outcomes in patients with adenocarcinoma of the anal canal.
  • METHODS: A retrospective consecutive cohort study of all patients in whom adenocarcinoma of the anal canal was diagnosed between 1983 and 2004 was performed.
  • RESULTS: Thirty-four patients were identified; six underwent palliative treatment (Stage IV, n = 4; poor performance, n = 2).
  • CONCLUSION: Combined modality treatment with radical surgical resection improves survival among patients with adenocarcinoma of the anal canal, but a high risk for distant failure emphasizes the need for effective adjuvant therapeutic regimens.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anus Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617747.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Schöllnberger H, Stewart RD, Mitchel RE: Low-LET-induced radioprotective mechanisms within a stochastic two-stage cancer model. Dose Response; 2005;3(4):508-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-LET-induced radioprotective mechanisms within a stochastic two-stage cancer model.
  • A stochastic two-stage cancer model with clonal expansion was used to investigate the potential impact on human lung cancer incidence of some aspects of the hormesis mechanisms suggested by Feinendegen (Health Phys.
  • Sensitivity studies were conducted to identify critical model inputs and to help define the changes in cellular defense mechanisms necessary to produce a lifetime probability for lung cancer that deviates from a linear no-threshold (LNT) type of response.
  • Our studies suggest that lung cancer risk predictions may be very sensitive to the induction of DNA damage by endogenous processes.
  • For an additional lifetime dose of 1 Gy from low-LET radiation, endogenous processes may still account for as much as 20% of the predicted cancers (Fig. 2).
  • When both repair and scavengers are considered as inducible, radiation must enhance DNA repair and radical scavenging in excess of 30 to 40% of the baseline values to produce lifetime probabilities for lung cancer outside the range expected for endogenous processes and background radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):674-9 [11237389.001]
  • [Cites] Radiat Res. 2002 Aug;158(2):181-6 [12105988.001]
  • [Cites] Int J Radiat Biol. 2000 Oct;76(10):1365-75 [11057745.001]
  • [Cites] Radiat Res. 2000 Aug;154(2):178-86 [10931690.001]
  • [Cites] Mutat Res. 2000 Jan 17;447(1):73-116 [10686307.001]
  • [Cites] Mutat Res. 1999 Sep 13;435(1):43-61 [10526216.001]
  • [Cites] Int J Radiat Biol. 1999 Sep;75(9):1189-99 [10528927.001]
  • [Cites] Radiat Res. 1999 Sep;152(3):273-9 [10453088.001]
  • [Cites] Radiat Environ Biophys. 1999 May;38(1):57-71 [10384956.001]
  • [Cites] Science. 1998 May 15;280(5366):1066-9 [9582118.001]
  • [Cites] Radiat Res. 1998 May;149(5):517-20 [9588363.001]
  • [Cites] Radiat Environ Biophys. 1997 Jun;36(2):85-8 [9271795.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Radiat Environ Biophys. 1997 Feb;36(1):45-58 [9128898.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Radiat Res. 1996 Nov;146(5):582-5 [8896586.001]
  • [Cites] Radiat Res. 1996 Oct;146(4):369-73 [8927708.001]
  • [Cites] Mutat Res. 1996 Sep 23;356(2):209-16 [8841487.001]
  • [Cites] Histol Histopathol. 1996 Jan;11(1):237-55 [8720467.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1278-91 [8589222.001]
  • [Cites] Risk Anal. 1994 Dec;14(6):1079-80 [7846315.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] Risk Anal. 1993 Jun;13(3):273-9 [8341806.001]
  • [Cites] Free Radic Biol Med. 1991;11(3):299-306 [1937147.001]
  • [Cites] N Engl J Med. 1989 Nov 9;321(19):1285-9 [2797101.001]
  • [Cites] Risk Anal. 1990 Jun;10(2):323-41 [2195604.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] J Natl Cancer Inst. 1978 Jul;61(1):49-52 [276637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6 [14610281.001]
  • [Cites] Int J Radiat Biol. 2003 Apr;79(4):235-40 [12775447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):767-74 [12618888.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):691-2 [12610596.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):433-6 [12600247.001]
  • [Cites] Ann ICRP. 2006;36(1-2):25-327, iii [17188183.001]
  • [Cites] Risk Anal. 2001 Feb;21(1):103-5 [11332539.001]
  • [Cites] Radiat Res. 2001 Dec;156(6):700-7 [11741493.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):320-7 [12600234.001]
  • [Cites] Int J Radiat Biol. 2002 Dec;78(12):1139-47 [12556341.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4115-39 [11205238.001]
  • (PMID = 18648628.001).
  • [ISSN] 1559-3258
  • [Journal-full-title] Dose-response : a publication of International Hormesis Society
  • [ISO-abbreviation] Dose Response
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2477198
  • [Keywords] NOTNLM ; LNT / endogenous damage / hormesis / low-LET / lung cancer / radioprotective mechanisms / threshold
  •  go-up   go-down


80. Winter L, Bruhn H, Langrehr J, Neuhaus P, Felix R, Hänninen LE: Magnetic resonance imaging in suspected rectal cancer: determining tumor localization, stage, and sphincter-saving resectability at 3-Tesla-sustained high resolution. Acta Radiol; 2007 May;48(4):379-87
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging in suspected rectal cancer: determining tumor localization, stage, and sphincter-saving resectability at 3-Tesla-sustained high resolution.
  • PURPOSE: To assess image quality and overall accuracy of 3-Tesla (3T)-sustained high-resolution magnetic resonance (MR) imaging for diagnostic preoperative workup in suspected rectal carcinoma.
  • MATERIAL AND METHODS: Twenty-three patients with suspected rectal cancer underwent unenhanced and contrast-enhanced fat-suppressed pelvic high-resolution MR imaging using a four-channel phased-array pelvic coil at 3T.
  • Image quality, tumor stage, distance from the anorectal margin, and sphincter-saving resectability were prospectively assessed by two blinded readers.
  • T stage and N stage were correctly diagnosed in 95% and 91%, respectively.
  • CONCLUSION: MR imaging with phased-array receiver coils at 3T facilitated both visualization of different pathologic conditions of the rectum and accurate determination of tumor stage in rectal carcinomas.
  • Thus, this noninvasive diagnostic approach appeared highly suitable for the assessment of patients with suspected rectal carcinoma.
  • [MeSH-major] Anal Canal / surgery. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453515.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


81. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • Initial tumors were AJCC stage 2 (16 cases), 3A (3 cases), and 4 (1 case).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


82. Kagawa R, Yamaguchi T, Furuta R: Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma. Surg Today; 2006;36(10):885-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma.
  • PURPOSE: To investigate the development of anal squamous cell carcinoma (SCC) and the expression patterns of human papillomavirus (HPV).
  • The expression patterns of HPV in the cancer cell nuclei was investigated by in situ hybridization (ISH) using HPV probes.
  • RESULTS: Amplification of DMD genes was confirmed in 8 of 20 patients with anal SCC, suggesting that tumor DNA was preserved in these patients.
  • In two patients with carcinoma in situ (CIS), the cancer cells showed only a diffuse pattern (DP), and in two patients with invasive cancer, the cancer cell showed only an oligo-dot pattern (OP).
  • In one patient with lesions ranging from CIS to invasive cancer, the histologic features varied in each area, from DP to OP.
  • CONCLUSIONS: These findings show that HPV16 infection is closely involved in the development of anal SCC and suggest that the change in the genome occurs at the stage of microinvasive cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. DNA, Viral / genetics. Human papillomavirus 16 / genetics. Papillomavirus Infections / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998682.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


83. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • There were 9 stage I, 29 stage II, 11 stage IIIa and 13 stage IIIb.
  • RESULTS: Stage II fared significantly better than stage III in terms of locoregional control (LRC) but not overall survival (OS).
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


84. Sharma P, Kumar N, Bahadur AK, Shukla DK: Quantitative analysis of radiation-associated cellular changes in oral cancer and their correlations with histologic grade and clinical stage: a multivariate evaluation of 43 patients. Anal Quant Cytol Histol; 2005 Apr;27(2):111-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of radiation-associated cellular changes in oral cancer and their correlations with histologic grade and clinical stage: a multivariate evaluation of 43 patients.
  • OBJECTIVE: To quantitate radiation-associated cytologic abnormalities in oral cancer cells and analyze their relationships with radiation dose, clinical stage and histologic grade.
  • STUDY DESIGN: Forty-three oral cancer patients receiving 2 Gy of fractionated radiotherapy per day were enrolled.
  • The variation in these counts with increasing radiation dose was assessed and compared with the histologic grade and clinical stage.
  • Most cytologic features were not significantly different in early and advanced clinical stage cancers before or after irradiation (Mann-Whitney U test).
  • CONCLUSION: Cellular changes do not show a relationship with clinical stage either before or after irradiation.
  • Since micronucleation and nuclear budding remain significantly different between histologic grades even after 24 Gy of irradiation, they may be utilized as clinically practicable alternatives to biopsy at this stage and may be useful in further studies on cytologic prognostication of irradiated oral cancer.

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913204.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Nibbe RK, Markowitz S, Myeroff L, Ewing R, Chance MR: Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. Mol Cell Proteomics; 2009 Apr;8(4):827-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer.
  • We used a systems biology approach to identify and score protein interaction subnetworks whose activity patterns are discriminative of late stage human colorectal cancer (CRC) versus control in colonic tissue.
  • We conducted two gel-based proteomics experiments to identify significantly changing proteins between normal and late stage tumor tissues obtained from an adequately sized cohort of human patients.
  • Based on this scoring, the subnetwork was pruned to identify the specific protein combinations that were significantly discriminative of late stage cancer versus control.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2001 Sep 3;20(17):4935-43 [11532957.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7373-80 [16767159.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4855-62 [12101425.001]
  • [Cites] Proteomics. 2003 Mar;3(3):288-98 [12627382.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):931-46 [12631590.001]
  • [Cites] Cancer Sci. 2003 Feb;94(2):148-52 [12708489.001]
  • [Cites] Proteomics. 2004 Mar;4(3):793-811 [14997500.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1206-14 [15247132.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Gut. 1992 Mar;33(3):342-6 [1568652.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1736-40 [8127874.001]
  • [Cites] FEBS Lett. 2005 Mar 21;579(8):1834-8 [15763560.001]
  • [Cites] Cell Death Differ. 2007 Jan;14(1):137-45 [16645643.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5401-6 [17372198.001]
  • [Cites] Nat Protoc. 2006;1(3):1351-8 [17406422.001]
  • [Cites] PLoS Comput Biol. 2007 Mar 30;3(3):e42 [17397251.001]
  • [Cites] Mol Syst Biol. 2007;3:140 [17940530.001]
  • [Cites] Mol Syst Biol. 2007;3:141 [17940531.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Mol Cell Proteomics. 2007 Dec;6(12):2072-87 [17855441.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):587-95 [18212756.001]
  • [Cites] PLoS Comput Biol. 2008 Feb;4(2):e28 [18282083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 13;105(19):6959-64 [18474861.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2050-8 [15688023.001]
  • [Cites] Anal Bioanal Chem. 2005 Jun;382(3):669-78 [15900442.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2587-601 [15912508.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2602-11 [15924290.001]
  • [Cites] World J Gastroenterol. 2005 Sep 28;11(36):5644-50 [16237758.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1949-55 [16488993.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):809-17 [16648550.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1329-38 [16439467.001]
  • [Cites] Mol Cell Proteomics. 2006 Jun;5(6):1119-30 [16554294.001]
  • [Cites] Methods Mol Biol. 2007;356:319-50 [16988414.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15079-84 [17005722.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2567-74 [16988946.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):523-31 [11920611.001]
  • (PMID = 19098285.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / T32-GM008803; United States / NCRR NIH HHS / RR / UL1 RR024989; United States / NCRR NIH HHS / RR / UL1-RR024989; United States / NCI NIH HHS / CA / P30 CA043703; United States / NIGMS NIH HHS / GM / T32 GM008803; United States / NCI NIH HHS / CA / P30-CA043703
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2667362
  •  go-up   go-down


86. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Xia P, An HX, Dang CX, Radpour R, Kohler C, Fokas E, Engenhart-Cabillic R, Holzgreve W, Zhong XY: Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer; 2009;9:454
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer.
  • We sought to investigate whether mtDNA content in the peripheral blood of breast cancer patients is associated with clinical and pathological parameters.
  • METHODS: Peripheral blood samples were collected from 60 patients with breast cancer and 51 age-matched healthy individuals as control.
  • A FAM labeled MGB probe and primers were used to amplify the mtDNA sequence of the ATP 8 gene, and a VIC labeled MGB probe and primers were employed to amplify the glyceraldehyde-3-phosphate-dehydrogenase gene. mtDNA content was correlated with tumor stage, menstruation status, and age of patients as well as lymph node status and the expression of estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu protein.
  • RESULTS: The content of mtDNA in stage I breast cancer patients was significantly lower than in other stages (overall P = 0.023).
  • Reduced mtDNA was found often in post menopausal cancer group (P = 0.024).
  • CONCLUSION: Early detection of breast cancer has proved difficult and current detection methods are inadequate.
  • In the present study, decreased mtDNA content in the peripheral blood of patients with breast cancer was strongly associated with stage I.
  • The use of mtDNA may have diagnostic value and further studies are required to validate it as a potential biomarker for early detection of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mitochondrion. 2007 Dec;7(6):386-95 [17981517.001]
  • [Cites] IUBMB Life. 2007 Jul;59(7):450-7 [17654121.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):798-805 [18258989.001]
  • [Cites] Breast Cancer Res Treat. 2008 Apr;108(3):427-34 [17541740.001]
  • [Cites] Breast. 2008 Oct;17(5):540-2 [18571924.001]
  • [Cites] Nat Rev Cancer. 2008 Sep;8(9):705-13 [19143055.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Aug;135(8):983-9 [19125299.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1299-304 [11245424.001]
  • [Cites] Clin Chem. 2003 May;49(5):719-26 [12709361.001]
  • [Cites] Nucleic Acids Res. 2003 Jun 1;31(11):e61 [12771225.001]
  • [Cites] Expert Rev Mol Med. 2002 Apr;4(9):1-19 [14987393.001]
  • [Cites] Mutat Res. 2004 Mar 22;547(1-2):71-8 [15013701.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2390-6 [15150555.001]
  • [Cites] Am J Clin Nutr. 1986 Nov;44(5):614-9 [3766447.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):592-9 [8600309.001]
  • [Cites] Physiol Behav. 1995 Dec;58(6):1067-77 [8623004.001]
  • [Cites] Mol Hum Reprod. 1997 Feb;3(2):133-48 [9239718.001]
  • [Cites] Brain Res Mol Brain Res. 1997 Dec 15;52(2):284-9 [9495550.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Methods Mol Biol. 2005;297:13-30 [15570097.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2486-91 [15814624.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):104-10 [15921730.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):19-28 [15892105.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1564-9 [16533782.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:79-99 [16704336.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1087-91 [17047655.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):421-6 [17255261.001]
  • [Cites] Anal Biochem. 2007 Mar 15;362(2):193-200 [17270140.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):121-31 [17311537.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):53-7 [17320491.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):408-17 [18196528.001]
  • (PMID = 20025731.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ PMC2803198
  •  go-up   go-down


88. Fujita S, Yamamoto S, Akasu T, Moriya Y: Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy. Int J Colorectal Dis; 2008 Nov;23(11):1073-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy.
  • BACKGROUND: To clarify the indications for preoperative adjuvant radiotherapy for rectal cancer, the outcome of patients who underwent curative surgery without adjuvant radiotherapy was investigated.
  • METHODS: A total of 817 consecutive patients who underwent curative surgery for clinical stage II or III rectal cancer without preoperative adjuvant radiotherapy between 1988 and 2002 were reviewed.
  • Univariate analysis showed that sex, pathological T classification (pT), clinical N classification (cN), pathological N classification (pN), tumor site, distance from the anal verge, type of surgery, pathological stage, a positive radical margin, lymphatic invasion, and venous invasion were significantly correlated with local recurrence.
  • Multivariate analysis of preoperative factors identified cN, distance from the anal verge, and sex as statistically significant risk factors for local recurrence.
  • In patients with rectal cancer located less than 5 cm from the anal verge and with positive cN, the local recurrence rate was more than 10%.
  • CONCLUSIONS: Patients with rectal cancer located less than 5 cm from the anal verge and with clinically positive lymph nodes should be given preoperative adjuvant radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594841.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


89. Hoshikawa T, Mukai M, Oida Y, Tajima T, Morikawa G, Nakamura T, Motojyuku M, Nakamura M, Makuuchi H: Pelvic recurrence after Miles' operation for anastomotic recurrence in a patient with stage I rectal cancer invading the proper muscle layer: Case report. Oncol Rep; 2007 Apr;17(4):743-6
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic recurrence after Miles' operation for anastomotic recurrence in a patient with stage I rectal cancer invading the proper muscle layer: Case report.
  • We performed D2 low anterior resection in a patient with stage I rectal cancer [pathological diagnosis: proper muscle (pm) invasion, n0, lymphatic invasion (ly), (-); venous invasion (v), (-); anal margin, (-)].
  • These findings suggest that the risk of local recurrence of rectal cancer is increased even in stage I disease if ONCs are found in the perinodal fat.
  • Further studies are required to examine the relationship between local recurrence and extranodal ONCs in patients with primary rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342309.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


90. Wang Y, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR, Giordano TJ, Shedden KA, Misek DE, Lubman DM: Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. J Proteome Res; 2009 Mar;8(3):1452-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage.
  • Ovarian serous carcinomas (OSCs) comprise over half of all ovarian carcinomas and account for the majority of ovarian cancer-related deaths.
  • We used a 2-dimensional liquid-based protein mapping strategy to characterize global protein expression patterns in 19 OSC tumor samples from 15 different patients to facilitate molecular classification of tumor stage.
  • The 19 tumor samples could be classified into two different groups, one group associated with low stage (Stage 1) tumors and the other group associated with high stage (Stages 3/4) tumors.
  • Fourteen of the selected proteins were overexpressed in the low stage tumors; 46 of the proteins were overexpressed in the high stage tumors.
  • To further confirm the stage-dependent protein identifications, Lamin A/C and Vimentin expression in ovarian serous carcinomas was assessed by immunohistochemistry using ovarian tumor tissue microarrays for 66 samples.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):895-9 [11948469.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6674-81 [12438266.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2913-22 [12782598.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1589-94 [14996714.001]
  • [Cites] Proteomics. 2004 Mar;4(3):562-77 [14997480.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3814-22 [15172988.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Proteomics. 2004 Aug;4(8):2476-95 [15274142.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2896-903 [7796418.001]
  • [Cites] Obstet Gynecol. 1995 Aug;86(2):259-64 [7617357.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):663-7 [9237175.001]
  • [Cites] J Urol. 1998 Jan;159(1):270-4 [9400493.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1115-21 [15555543.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1049-54 [15986428.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4625-36 [16220531.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):43-52 [16141455.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):476-9 [10600311.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):48-57 [10918393.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • [Cites] Anal Chem. 2002 Apr 15;74(8):1779-91 [11985308.001]
  • (PMID = 19159301.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM049500-12; United States / NCI NIH HHS / CA / R01 CA100104; United States / NIGMS NIH HHS / GM / R01GM49500; United States / NIGMS NIH HHS / GM / GM049500-11A2; United States / NIGMS NIH HHS / GM / GM049500-12; United States / NIGMS NIH HHS / GM / R01 GM049500; United States / NCI NIH HHS / CA / R01CA100104; United States / NCI NIH HHS / CA / R01 CA100104-05; United States / NCI NIH HHS / CA / CA100104-05; United States / NIGMS NIH HHS / GM / R01 GM049500-11A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  • [Other-IDs] NLM/ NIHMS81647; NLM/ PMC2693455
  •  go-up   go-down


91. Chiao EY, Krown SE, Stier EA, Schrag D: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr; 2005 Dec 1;40(4):451-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic.
  • Squamous cell carcinoma of the anal canal (SCCA) is etiologically linked to human papillomavirus, and its incidence is increased among the immunosuppressed.
  • The gap in SCCA incidence between women and men decreased from a ratio of 1.6:1 in the pre-HIV era to 1.5:1 in the HIV era and to 1.2:1 in the HAART era.
  • Men were more likely to be diagnosed with early-stage disease, but they were less likely than women to receive radiation therapy.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. HIV Infections / epidemiology


92. Law WL, Chu KW: Outcomes of resection of stage IV rectal cancer with mesorectal excision. J Surg Oncol; 2006 Jun 1;93(7):523-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection of stage IV rectal cancer with mesorectal excision.
  • BACKGROUND: There is no consensus as to the management of the primary rectal cancer in the presence of distant metastasis and data on the outcomes of radical resection in stage IV rectal cancer are limited.
  • This study aims to evaluate the results of resection of rectal cancer in the patients with stage IV disease and to analyze the factors that might affect the survival of these patients.
  • METHODS: Of the 744 patients with radical resection of primary rectal and rectosigmoid cancer during the study period from August 1993 to July 2002, 70 had stage IV disease on the initial presentation.
  • The median level of the tumor from the anal verge was 10 cm (range 3-20 cm).
  • The median cancer-specific survival of the patients who survived the surgery was 15.2 months.
  • CONCLUSIONS: Postoperative mortality and morbidity were acceptable in patients with stage IV rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16705728.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Nakagawa S, Amano M, Yamashita S, Nishikawa Y, Higaki N, Hayashida H, Niinobu T, Yoshioka Y, Sakon M: [A case of effective chemoradiation therapy against anal fistula carcinoma recurred 10 years after surgery]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1977-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective chemoradiation therapy against anal fistula carcinoma recurred 10 years after surgery].
  • A male in his eighties underwent abdominoperineal resection under the diagnosis of adenocarcinoma associated with anal fistula (P0, H0, n (-), A1, stage II, ly0, v0).
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Rectal Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212165.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


94. Oehler-Jänne C, Seifert B, Lütolf UM, Ciernik IF: Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol; 2006;1:29
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.
  • PURPOSE: To investigate the outcome of HIV-seropositive patients under highly active antiretroviral treatment (HAART) with anal cancer treated with radiotherapy (RT) alone or in combination with standard chemotherapy (CT).
  • 10 TNM-stage and age matched HIV-seronegative patients (1992-2003) were compared with the 10 HIV-seropositive patients.
  • Pattern of care, local disease control (LC), overall survival (OS), cancer-specific survival (CSS), and toxicity were assessed.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Anus Neoplasms / virology. HIV Infections / complications. HIV Infections / drug therapy. Radiotherapy / methods


95. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C: Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol; 2010 Dec 1;28(34):5061-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
  • PURPOSE: To determine whether increased duration of radiation therapy (RT) and overall treatment (RX) time has a detrimental effect in anal cancer.
  • Cox proportional hazards models were used with the following variables: RT duration, RT intensity, RX duration, treatment group, age, sex, Karnofsky performance score (KPS), T stage, N stage, and RT dose.
  • Age, sex, KPS, T stage, N stage, and RT dose, but not RT duration, RT intensity, or RX duration, were found to be statistically significant predictors of OS and colostomy-free survival.
  • CONCLUSION: Total treatment time, but not duration of radiation therapy, seems to have a detrimental effect on local failure and colostomy rate in anal cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1994 Feb;30(2):109-20 [8184108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):428-35 [19251377.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):101-10 [10799721.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):187-94 [11325448.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):483-93 [11567825.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):693-701 [12424072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1074-81 [12605987.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):69-76 [12758242.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259-73 [12873670.001]
  • [Cites] Eur J Cancer. 1967 Nov;3(4):361-9 [6078936.001]
  • [Cites] Radiat Res. 1969 Feb;37(2):423-34 [5765551.001]
  • [Cites] Br J Radiol. 1973 May;46(545):381-7 [4715162.001]
  • [Cites] Cancer Res. 1976 Oct;36(10):3718-25 [953998.001]
  • [Cites] Br J Cancer. 1977 Sep;36(3):313-21 [921888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):321-8 [6841183.001]
  • [Cites] Acta Oncol. 1988;27(2):131-46 [3390344.001]
  • [Cites] Eur J Cancer. 1991;27(5):537-43 [1828958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1195-202 [1938517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1529-34 [1938563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):391-7 [8436516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1051-6 [8262826.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Lancet. 1998 May;351 Suppl 2:SII9-16 [9606361.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):525-32 [9778618.001]
  • [Cites] Acta Oncol. 2006;45(6):728-35 [16938816.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):114-8 [18472363.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):549-62 [7558943.001]
  • (PMID = 20956625.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3018356
  •  go-up   go-down


96. Nakayasu ES, Gaynor MR, Sobreira TJ, Ross JA, Almeida IC: Phosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stage. Proteomics; 2009 Jul;9(13):3489-506
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stage.
  • Our LC-MS/MS, dual-stage fragmentation, and multistage activation analysis has identified 237 phosphopeptides from 119 distinct proteins.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2000 Apr;113 ( Pt 7):1299-307 [10704380.001]
  • [Cites] Mol Biochem Parasitol. 2009 May;165(1):19-31 [19393159.001]
  • [Cites] Curr Opin Cell Biol. 2001 Apr;13(2):131-8 [11248545.001]
  • [Cites] Anal Chem. 2001 Apr 1;73(7):1440-8 [11321292.001]
  • [Cites] Int J Parasitol. 2001 May 1;31(5-6):472-81 [11334932.001]
  • [Cites] Mol Biochem Parasitol. 2002 Feb;119(2):265-71 [11814578.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25493-501 [11964410.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2002 Jul;97(5):603-12 [12219120.001]
  • [Cites] J Mass Spectrom. 1999 Feb;34(2):117-23 [12440389.001]
  • [Cites] Eukaryot Cell. 2002 Feb;1(1):137-51 [12455980.001]
  • [Cites] Eukaryot Cell. 2003 Apr;2(2):200-8 [12684369.001]
  • [Cites] Microbes Infect. 2003 Apr;5(5):419-27 [12737998.001]
  • [Cites] Traffic. 2003 Jul;4(7):435-42 [12795688.001]
  • [Cites] Nat Rev Drug Discov. 2003 Sep;2(9):717-26 [12951578.001]
  • [Cites] Trends Parasitol. 2003 Nov;19(11):495-501 [14580960.001]
  • [Cites] Lancet. 2003 Nov 1;362(9394):1469-80 [14602444.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 11;1697(1-2):155-68 [15023358.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 11;1697(1-2):181-96 [15023360.001]
  • [Cites] Circulation. 2004 Mar 16;109(10):1196-205 [15023894.001]
  • [Cites] Nat Rev Drug Discov. 2004 Jun;3(6):479-87 [15173837.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2250-9 [15181573.001]
  • [Cites] Anal Chem. 2004 Jul 1;76(13):3590-8 [15228329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12130-5 [15302935.001]
  • [Cites] EMBO J. 1993 Feb;12(2):803-8 [8382613.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14566-74 [7514173.001]
  • [Cites] J Biol Chem. 1996 Jun 28;271(26):15675-81 [8663171.001]
  • [Cites] Exp Parasitol. 1998 Jun;89(2):188-94 [9635442.001]
  • [Cites] J Am Soc Mass Spectrom. 1998 Nov;9(11):1175-88 [9794085.001]
  • [Cites] Mol Biochem Parasitol. 1999 Jun 25;101(1-2):61-70 [10413043.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 1964 May-Jun;6:93-100 [14177814.001]
  • [Cites] Mol Biochem Parasitol. 2005 Mar;140(1):75-86 [15694489.001]
  • [Cites] Gene. 2005 Feb 14;346:153-61 [15716016.001]
  • [Cites] Int J Parasitol. 2005 Apr 30;35(5):555-66 [15826647.001]
  • [Cites] Science. 2005 Jul 15;309(5733):409-15 [16020725.001]
  • [Cites] BMC Genomics. 2005;6:127 [16164760.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 30;1754(1-2):151-9 [16198642.001]
  • [Cites] Expert Rev Vaccines. 2005 Dec;4(6):867-80 [16372882.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D428-31 [16381904.001]
  • [Cites] Nature. 2006 Mar 9;440(7081):224-7 [16525475.001]
  • [Cites] Cell. 2006 Nov 3;127(3):635-48 [17081983.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):623-34 [17100568.001]
  • [Cites] J Proteome Res. 2006 Dec;5(12):3376-84 [17137339.001]
  • [Cites] Toxicon. 2007 Mar 1;49(3):339-50 [17134729.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 30;355(1):16-22 [17292866.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2171-81 [18000201.001]
  • [Cites] BMC Genomics. 2007;8:434 [18039372.001]
  • [Cites] Proteomics. 2008 Jan;8(2):350-63 [18203260.001]
  • [Cites] Genome Biol. 2007;8(11):R250 [18039369.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5022-7 [18367671.001]
  • [Cites] Proteomics. 2008 May;8(9):1843-50 [18398879.001]
  • [Cites] Nucleic Acids Res. 2008 Jun;36(10):3420-35 [18445632.001]
  • [Cites] Transfusion. 2008 Sep;48(9):1862-8 [18522707.001]
  • [Cites] Proteomics. 2008 Nov;8(21):4444-52 [18972524.001]
  • [Cites] J Proteome Res. 2009 Feb;8(2):887-99 [19072539.001]
  • [Cites] Eukaryot Cell. 2009 Apr;8(4):617-26 [19181871.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1304-51 [11181995.001]
  • (PMID = 19579231.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 5G12RR008124; United States / NIGMS NIH HHS / GM / 5S06GM08012-37; United States / NCRR NIH HHS / RR / G12 RR008124; United States / NIGMS NIH HHS / GM / S06 GM008012; United States / NIGMS NIH HHS / GM / GM008012-370002; United States / NIGMS NIH HHS / GM / S06 GM008012-370002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Protozoan; 0 / Phosphoproteins; 0 / Protozoan Proteins; 0 / RNA, Protozoan; 17885-08-4 / Phosphoserine
  • [Other-IDs] NLM/ NIHMS108555; NLM/ PMC2752742
  •  go-up   go-down


97. Forrester S, Hung KE, Kuick R, Kucherlapati R, Haab BB: Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer. Mol Oncol; 2007 Sep;1(2):216-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer.
  • Mouse models of human cancers may provide a valuable resource for the discovery of cancer biomarkers.
  • We used this method to profile the levels of 14 different cytokines, acute-phase reactants, and other cancer markers in plasma from a mouse models of intestinal tumors and their wild-type littermates, using as little as 1.5 microliters of diluted plasma per assay.
  • Many of the proteins were up-regulated even in the mutant mice with few or no tumors, suggesting the presence of a systemic host response at an early stage of cancer development.
  • These results have implications for the study of host responses in mouse models of cancers and demonstrate the value of a new low-volume, high-throughput sandwich-immunoassay method for sensitively profiling protein levels in cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):40-8 [17320282.001]
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):243-55 [10986418.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7585-93 [11606398.001]
  • [Cites] Cytokine. 2001 Dec 21;16(6):251-7 [11884029.001]
  • [Cites] Nat Biotechnol. 2002 Apr;20(4):359-65 [11923841.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):243-52 [12671663.001]
  • [Cites] Anal Chem. 2004 Apr 1;76(7):1832-7 [15053640.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Cytokine. 1993 Jul;5(4):319-26 [8260597.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Proteomics. 2005 Apr;5(5):1281-91 [15732136.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):4999s-5003s [16000603.001]
  • [Cites] BMC Cancer. 2005;5:110 [16117833.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1955-61 [16081503.001]
  • [Cites] Nat Rev Drug Discov. 2006 Apr;5(4):310-20 [16582876.001]
  • [Cites] Methods Mol Biol. 2006;328:31-50 [16785640.001]
  • [Cites] J Proteome Res. 2006 Aug;5(8):1866-78 [16889408.001]
  • [Cites] Curr Opin Biotechnol. 2006 Aug;17(4):415-21 [16837184.001]
  • [Cites] OMICS. 2006 Fall;10(3):411-27 [17069517.001]
  • [Cites] Genome Biol. 2001;2(2):RESEARCH0004 [11182887.001]
  • [Cites] Anal Biochem. 2001 Jul 1;294(1):55-62 [11412006.001]
  • (PMID = 19305640.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK078033-01; United States / NIDDK NIH HHS / DK / K08 DK078033; United States / NCI NIH HHS / CA / F012596; United States / NIDDK NIH HHS / DK / 1K08DK078033-01; United States / PHS HHS / / F012596; United States / NIDDK NIH HHS / DK / DK078033-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Cytokines; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS34888; NLM/ PMC2658882
  •  go-up   go-down


98. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE: Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol; 2009 Aug 10;27(23):3808-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
  • PATIENTS AND METHODS: Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation.
  • Response was classified using the National Cancer Institute (NCI) Working Group (WG) Criteria.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2000 Mar 15;279(2):164-9 [10706785.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):844-50 [11259102.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13322-30 [11278274.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:25-54 [11807163.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):381-5 [11809684.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]
  • [Cites] Arch Pharm Res. 2002 Oct;25(5):561-71 [12433185.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):824-30 [12591733.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Curr Treat Options Oncol. 2003 Jun;4(3):211-8 [12718798.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3312-9 [12960117.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 1;66(9):1769-78 [14563487.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7563-70 [14633667.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8118-21 [14678963.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] Toxicol In Vitro. 2004 Oct;18(5):555-61 [15251172.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1567-74 [15090467.001]
  • [Cites] Hematol Oncol. 1988 Jan-Mar;6(1):7-12 [3277904.001]
  • [Cites] Br J Haematol. 1989 Jun;72(2):141-9 [2757960.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):323-8 [8170175.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):393-9 [7655336.001]
  • [Cites] Leukemia. 1996 Mar;10(3):456-9 [8642861.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):134-5 [9296488.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 17;89(24):1881-6 [9414176.001]
  • [Cites] Leuk Lymphoma. 1997 Nov;27(5-6):523-32 [9477135.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 19;249(2):391-6 [9712707.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2059-64 [15781612.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4627-33 [15958649.001]
  • [Cites] Leuk Res. 2006 Jun;30(6):707-12 [16325256.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1227-38 [16731755.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):435-47 [16983131.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2804-10 [16809610.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):223S-228S [17182830.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):252-60 [17477351.001]
  • [Cites] Life Sci. 2007 Jul 26;81(7):519-33 [17655876.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):395-402 [17686632.001]
  • [Cites] Blood. 2008 Jan 15;111(2):846-55 [17928528.001]
  • [Cites] J Cell Biochem. 2008 Feb 1;103(2):509-19 [17570133.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):537-46 [18275431.001]
  • [Cites] Antioxid Redox Signal. 2008 Mar;10(3):475-510 [18154485.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Cancer Lett. 2008 Oct 8;269(2):269-80 [18501505.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1830-8 [11251015.001]
  • (PMID = 19470922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / R01 CA136591; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CA / CA6912
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tea; 0 / polyphenon E; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  • [Other-IDs] NLM/ PMC2727287
  •  go-up   go-down


99. Shao C, Xiong S, Li GM, Gu L, Mao G, Markesbery WR, Lovell MA: Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic Biol Med; 2008 Sep 15;45(6):813-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain.
  • Eight-hydroxy-2'-deoxyguanosine (8-OHdG) is increased in the brain in late-stage Alzheimer's disease (LAD) and mild cognitive impairment (MCI).

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Neurol. 2006 Jan;63(1):38-46 [16401735.001]
  • [Cites] Neurology. 2005 Apr 12;64(7):1152-6 [15824339.001]
  • [Cites] Neurobiol Aging. 2006 May;27(5):657-62 [15979765.001]
  • [Cites] Neurochem Res. 2006 May;31(5):705-10 [16770743.001]
  • [Cites] Neurobiol Aging. 2006 Aug;27(8):1094-9 [15993986.001]
  • [Cites] Neurobiol Aging. 2006 Aug;27(8):1129-36 [16005114.001]
  • [Cites] Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2039-45 [17034348.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):2759-66 [17426120.001]
  • [Cites] Nucleic Acids Res. 2007;35(16):5545-55 [17704129.001]
  • [Cites] Neurobiol Dis. 2008 Feb;29(2):169-75 [17920285.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4690-4 [2052552.001]
  • [Cites] Acta Neuropathol. 1991;82(4):239-59 [1759558.001]
  • [Cites] Free Radic Res Commun. 1992;16(2):75-87 [1321076.001]
  • [Cites] Ann Neurol. 1993 Oct;34(4):609-16 [8215249.001]
  • [Cites] Ann Neurol. 1994 Nov;36(5):747-51 [7979220.001]
  • [Cites] Free Radic Biol Med. 1995 Jun;18(6):1033-77 [7628729.001]
  • [Cites] Mutat Res. 1995 Oct;338(1-6):115-28 [7565867.001]
  • [Cites] J Neurochem. 1997 May;68(5):2061-9 [9109533.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2151-6 [9187114.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7429-34 [9207108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8016-20 [9223306.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25409-12 [9325246.001]
  • [Cites] Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2 [9330978.001]
  • [Cites] Neurobiol Aging. 1997 Sep-Oct;18(5):457-61 [9390770.001]
  • [Cites] Neurobiol Aging. 1998 Jan-Feb;19(1):33-6 [9562500.001]
  • [Cites] Brain Res. 2000 Feb 7;855(1):116-23 [10650137.001]
  • [Cites] Ann N Y Acad Sci. 1999;893:362-4 [10672267.001]
  • [Cites] Arch Biochem Biophys. 2000 May 1;377(1):1-8 [10775435.001]
  • [Cites] Curr Biol. 2000 Jun 1;10(11):R412-5 [10837244.001]
  • [Cites] FASEB J. 2000 Jul;14(10):1325-34 [10877825.001]
  • [Cites] Neurobiol Aging. 2001 Mar-Apr;22(2):187-94 [11182468.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67 [11487050.001]
  • [Cites] Mutat Res. 2001 Nov 1;487(1-2):19-30 [11595405.001]
  • [Cites] Acta Neuropathol. 2002 Jan;103(1):20-5 [11837743.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1102-15 [12031895.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 2;1592(1):63-77 [12191769.001]
  • [Cites] Neuroreport. 2002 Nov 15;13(16):2035-9 [12438921.001]
  • [Cites] J Radiat Res. 2003 Mar;44(1):31-5 [12841596.001]
  • [Cites] J Am Chem Soc. 2003 Sep 24;125(38):11607-15 [13129365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10670-5 [12960370.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • [Cites] Neurology. 1989 Sep;39(9):1159-65 [2771064.001]
  • [Cites] Nature. 1991 Jan 31;349(6308):431-4 [1992344.001]
  • [Cites] Neurology. 1991 Apr;41(4):479-86 [2011243.001]
  • [Cites] J Neurochem. 2005 May;93(4):953-62 [15857398.001]
  • [Cites] Anal Chem. 2005 May 15;77(10):3383-9 [15889933.001]
  • [Cites] J Neurosci. 2005 Oct 5;25(40):9171-5 [16207876.001]
  • [Cites] Curr Alzheimer Res. 2005 Oct;2(4):403-8 [16248845.001]
  • [Cites] J Comp Physiol B. 1998 Apr;168(3):149-58 [9591361.001]
  • [Cites] J Neurochem. 1998 Nov;71(5):2034-40 [9798928.001]
  • [Cites] Nucleic Acids Res. 1999 Apr 15;27(8):1935-42 [10101204.001]
  • [Cites] Mol Biol Cell. 1999 May;10(5):1637-52 [10233168.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1423-9 [10329595.001]
  • [Cites] J Neurochem. 2006 Feb;96(3):825-32 [16405502.001]
  • (PMID = 18598755.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / 5-P30-AG028383; United States / NIA NIH HHS / AG / AG005119-20A10009; United States / NIA NIH HHS / AG / P01 AG005119; United States / NIA NIH HHS / AG / 5-P01-AG05119; United States / NIA NIH HHS / AG / P01 AG005119-20A10009; United States / NIA NIH HHS / AG / P01 AG005119-20A1; United States / NIA NIH HHS / AG / P30 AG028383; United States / NIA NIH HHS / AG / P30 AG028383-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human
  • [Other-IDs] NLM/ NIHMS105232; NLM/ PMC2745061
  •  go-up   go-down


100. Fariña-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ: TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Anal Cell Pathol (Amst); 2010;33(1):1-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
  • AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
  • With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.
  • PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected.
  • RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05).In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found.
  • CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966539.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4605551
  •  go-up   go-down






Advertisement